

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Thrombolysis, Time-to-Treatment and In-Hospital Outcomes Among Young Adults with Ischemic Stroke in China

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-055055
Article Type:	Original research
Date Submitted by the Author:	01-Jul-2021
Complete List of Authors:	<p>Wang, HaiYan; Capital Medical University Affiliated Beijing Shijitan Hospital, Department of Neurology</p> <p>Gu, Hongqiu; Beijing Tiantan Hospital, China National Clinical Research Center for Neurological Diseases; Beijing Tiantan Hospital, National Center for Healthcare Quality Management in Neurological Diseases</p> <p>Zhou, Qi; Beijing Tiantan Hospital, China National Clinical Research Center for Neurological Diseases; Beijing Tiantan Hospital, National Center for Healthcare Quality Management in Neurological Diseases</p> <p>Jiang, YingYu; Beijing Tiantan Hospital, China National Clinical Research Center for Neurological Diseases; Beijing Tiantan Hospital, National Center for Healthcare Quality Management in Neurological Diseases</p> <p>Yang, Xin; Beijing Tiantan Hospital, China National Clinical Research Center for Neurological Diseases; Beijing Tiantan Hospital, National Center for Healthcare Quality Management in Neurological Diseases</p> <p>Wang, Chunjuan; Beijing Tiantan Hospital, China National Clinical Research Center for Neurological Diseases; Beijing Tiantan Hospital, National Center for Healthcare Quality Management in Neurological Diseases</p> <p>Zhao, Xingquan; Beijing Tiantan Hospital, Vascular Neurology, Department of Neurology; Research Unit of Artificial Intelligence in Cerebrovascular Disease, Chinese Academy of Medical Sciences</p> <p>Wang, Yilong; Beijing Tiantan Hospital, China National Clinical Research Center for Neurological Diseases; Beijing Tiantan Hospital, Vascular Neurology, Department of Neurology</p> <p>Liu, Liping; Beijing Tiantan Hospital, Neuro-intensive Care Unit, Department of Neurology</p> <p>Meng, Xia; Beijing Tiantan Hospital, China National Clinical Research Center for Neurological Diseases</p> <p>Li, Hao; Beijing Tiantan Hospital, China National Clinical Research Center for Neurological Diseases</p> <p>Liu, Chelsea; Harvard University T H Chan School of Public Health, Department of Epidemiology</p> <p>Li, Zixiao; Beijing Tiantan Hospital, China National Clinical Research Center for Neurological Diseases; Beijing Tiantan Hospital, National Center for Healthcare Quality Management in Neurological Diseases</p> <p>Wang, Yongjun; Beijing Tiantan Hospital, China National Clinical Research Center for Neurological Diseases; Beijing Tiantan Hospital, National Center for Healthcare Quality Management in Neurological Diseases</p> <p>Jiang, Yong; Beijing Tiantan Hospital, China National Clinical Research Center for Neurological Diseases</p>

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Keywords:	Adult neurology < NEUROLOGY, Stroke < NEUROLOGY, VASCULAR MEDICINE

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

Title Page

Thrombolysis, Time-to-Treatment and In-Hospital Outcomes Among Young Adults with Ischemic Stroke in China

Hai-Yan Wang¹ *; Hong-Qiu Gu^{2,3} *; Qi Zhou^{2,3}; Ying-Yu Jiang^{2,3}; Xin Yang^{2,3};
Chun-Juan Wang^{2,3}; Xing-Quan Zhao^{4,5}; Yi-Long Wang^{2,4}; Li-Ping Liu⁶; Xia Meng²;
Hao Li²; Chelsea Liu⁷; Zi-Xiao Li^{2,3}; Yong-Jun Wang^{2,3#}; Yong Jiang^{2#};

¹Department of Neurology, Beijing Shijitan Hospital, Capital Medical University, Beijing, China

²China National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University, Beijing, China

³National Center for Healthcare Quality Management in Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University, Beijing, China

⁴Vascular Neurology, Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China

⁵Research Unit of Artificial Intelligence in Cerebrovascular Disease, Chinese Academy of Medical Sciences, Beijing, China

⁶Neuro-intensive Care Unit, Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China

⁷Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA

⁸Beijing Key Laboratory of Translational Medicine for Cerebrovascular Disease, Beijing, China

⁹Center for Stroke, Beijing Institute for Brain Disorders, Beijing, China

* Hai-Yan Wang and Hong-Qiu Gu contributed equally to this paper.

#ADDRESS FOR CORRESPONDENCE

Yong-Jun Wang

China National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University

No.119 West Road, Southern Fourth Ring Road, Fengtai District, Beijing, China,
100070

Tel: 86-10-59975806

Email: yongjunwang@nccrncd.org.cn

1
2
3
4 Yong Jiang

5 China National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital
6 Medical University

7
8
9 No.119 West Road, Southern Fourth RingRoad, Fengtai District, Beijing, China,
10
11 100070

12
13 Tel: 86–10–59975806

14
15 Email: jiangyong@ncrcnd.org.cn
16
17

18
19
20
21 **Key words:** ischemic stroke, young stroke, thrombolysis, door-to-needle time
22
23

24
25
26 **Word Count:** 2758
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

ABSTRACT

Background and purpose We aimed to determine whether young adults (< 50 years) with acute ischemic stroke (AIS) are more likely to receive intravenous tissue plasminogen activator (IV tPA) and have shorter time to treatment than older stroke patients.

Methods We analyzed data from the Chinese Stroke Center Alliance (CSCA) registry for AIS patients hospitalized between August 2015 and July 2019. Patients were classified into two groups according to age: young adults (< 50 years of age) and older adults (\geq 50 years of age).

Results Of 79 3175 patients with AIS admitted to 1471 hospitals, 9.1% (71 860) were young adults. Compared to older adults, a higher proportion of young adults received IV tPA among patients without contraindications (7.2% vs. 6.1%, adjusted odds ratio [aOR] 1.13, 95% confidence interval [CI] 1.10-1.17) and among patients without contraindications and with onset-to-door time \leq 3.5h (23.6 % vs. 19.3%, aOR 1.20, 95% CI 1.15-1.24). We did not observe differences in onset-to-needle time (median hours 2.7h) or door-to-needle time (DNT) (median minutes 60m) between young and older adults. The proportion of DNT \leq 30 minutes, DNT \leq 45 minutes, and DNT \leq 60 minutes in young and older IV tPA treated patients were 16.9% vs 18.8%, 30.2% vs 32.8% and 50.2% vs 54.2%, respectively. Compared to older adults, young adults treated with IV tPA had lower odds of in-hospital mortality (0.5% vs 1.3%,

1
2
3
4 aOR 0.54, 95% CI 0.35-0.82) and higher odds of independent ambulation at discharge
5
6 (61.0% vs 53.6%, aOR 1.15, 95% CI 1.08-1.22), and the associations may be partly
7
8 explained by stroke severity measured by NIHSS score.
9
10

11
12 **Conclusion** Young adults with AIS were more likely to receive IV tPA than older
13
14 adults, though there was no difference between the two groups in time to treatment.
15
16 Compared with older adults, young adults may had better in-hospital outcomes.
17
18
19
20
21
22

23
24 **Key words:** ischemic stroke, young stroke, thrombolysis, door-to-needle time
25
26
27

28 **Strengths and limitations of this study**

- 29
30
31 1. We are one of the few authors to focus on the age difference in the status and
32
33 outcomes of intravenous thrombolysis;
34
35
36 2. Our data come from the Chinese Stroke Center Alliance registry, which is a national,
37
38 hospital-based, multicenter, voluntary, multifaceted intervention and continuous
39
40 quality improvement initiative and have stronger evidence level;
41
42
43 3. we believe that it is meaningful for further promotion of treatment for strokes,
44
45 especially for thrombolysis, because of providing a reference for the operator;
46
47
48 4. Since hospital participation in the CSCA is voluntary, participating hospitals are
49
50 more likely to be larger, tertiary centers with a myriad of resources that smaller
51
52 hospitals do not have access to;
53
54
55 5. We did not report data on intra-arterial (IA) therapies and puncture times.
56
57
58
59
60

ABBREVIATIONS

CSA: Chinese Stroke Association

CSCA: Chinese Stroke Center Alliance

QI: quality improvement

AIS: acute ischemic stroke

BMI: body mass index

mRS: modified Rankin Scale score

aOR: adjusted odds ratios

CI: confidence intervals

IV tPA: intravenous tissue plasminogen activator

IQR: interquartile range

NIHSS: National Institutes of Health Stroke Scale

DNT: door-to-needle time

sICH: symptomatic intracranial hemorrhage

INTRODUCTION

Stroke incidence among adults under 50 years of age has risen in recent years. [1-5]

This creates a significant socioeconomic burden due to high healthcare costs and loss

of labor productivity.[5,6] According to the 2019 Chinese Stroke Statistics, 81.9% of

stroke patients had ischemic strokes,[7] of which young adults constituted 15–18%.[8]

Given this trend, researchers must carefully consider the clinical features and best

practices of treatment for strokes in young adults.[8]

Ischemic stroke is a common, preventable, and treatable disease that typically results

from thrombotic or thromboembolic blockage of a cerebral artery.[9]

Revascularization therapy plays a major role in the process of saving penumbral tissue

from infarction. [10] Tissue plasminogen activator (tPA) is the only intravenous drug

approved for the treatment of acute ischemic stroke.[11] Treatment of acute occlusive

stroke with IV tPA is considered the most regular and important method when given

within 4.5 hours of occlusion.[12,13] While epidemiological studies have been done

in other countries regarding IV tPA treatment in young AIS patients, there is limited

research on this topic in China.[13-17]

The purpose of this study was to compare the characteristics, IV tPA treatment rates,

onset-to-needle time, door-to-needle time (DNT) and in-hospital outcomes of young

(<50 years of age) and older (\geq 50 years of age) AIS patients in the Chinese Stroke

Center Alliance (CSCA). We hypothesized that young AIS patients would be treated

more frequently with IV tPA, have shorter treatment time and better in-hospital

1
2
3
4 outcomes compared to older adults.
5
6
7
8
9

10 **METHODS**

11 **Data source**

12
13
14
15
16
17 CSCA is a national, hospital-based, multicentre, voluntary, multifaceted intervention
18
19 and continuous quality improvement initiative. The data coordinating center of CSCA
20
21 resides at the China National Clinical Research Center for Neurological Diseases
22
23 (NCRCCND), Beijing Tiantan Hospital. [18] Trained personnel collected patient
24
25 demographics, medical history, medications, DNT, and in-hospital outcomes, then
26
27 entered this information into a database using a web-based Patient Management Tool
28
29 (Medicine Innovation Research Center, Beijing, China). The tool is characterized by
30
31 predefined logic features, range checks, and user alerts to identify a potentially invalid
32
33 format or value entries and to optimize data quality at the time of entry. Training in
34
35 the use of the tool was provided online and onsite for all users. However, data
36
37 collected by hospitals were not independently audited by external chart review. In
38
39 addition, The China National Clinical Research Center for Neurological Diseases
40
41 serves as the data analysis center and has an agreement to analyze the aggregate
42
43 deidentified data for care quality feedback and research purposes. We abstracted 838
44
45 229 cases and identified 793 175 patients admitted with ischemic strokes from 2015 to
46
47
48
49
50
51
52
53
54
55
56
57
58 2019.
59
60

Study population

In the first stage, our analyses included patients admitted with AIS within 7 days of the onset of symptoms between August 1, 2015 and July 31, 2019 from 1473 hospitals. We excluded patients who had in-hospital strokes (n=7941, 0.95%), were missing IV tPA information (n=17461, 2.08%), had imprecise or undocumented arrival times (n=12), transferred in from an acute care hospital (n=1777, 0.212%), or had contraindications to venous thrombolysis within the time window (n=17863, 2.13%). This yielded a population of patients with ischemic strokes with indications for thrombolysis (n=793175). To analyze DNT and in-hospital outcomes of ischemic stroke, we excluded patients treated with IV tPA more than 4.5 hours after stroke onset (n=1315, 0.17%) and patients who were not treated with IV tPA (n=743719, 93.76%). This yielded a subset of the study population that consisted of 48141 AIS patients from 1290 hospitals (Figure 1).

Outcomes

The IV tPA treatment rate was assessed among two populations. First, IV tPA rate among patients without contraindications to thrombolytic therapy was calculated as the number of IV tPA cases divided by the total number of ischemic stroke cases without any contraindications to thrombolytic therapy. Then IV tPA rate among patients without contraindication to thrombolytic therapy and with onset-to-door time ≤ 3.5 h was calculated as the number of IV tPA cases divided by the total number of ischemic stroke cases without any contraindications to thrombolytic therapy and

1
2
3
4 arrived at a hospital within 3.5 hours after stroke onset. The contraindications were
5
6 defined according to guidelines for the early management of patients with acute
7
8 ischemic stroke from the Heart Association/American Stroke Association and Chinese
9
10 Society of Neurology. DNT was defined as the time between arrival at the emergency
11
12 department (ED) and time of intravenous (IV) thrombolysis, and is an important
13
14 metric in AIS treatment.[19,20] We analyzed DNT as a binary outcome three times
15
16 with a different cut-off point each time (≤ 30 , ≤ 45 , or ≤ 60 minutes, respectively).
17
18
19
20
21
22
23
24
25

26 In-hospital outcomes included symptomatic intracranial hemorrhage (sICH),
27
28 in-hospital mortality, and independent ambulation at discharge. sICH was defined as
29
30 intracranial hemorrhage (ICH) within 36 hours of admission, documented by CT or
31
32 MRI, with the treating physician's notes indicating clinical deterioration attributable
33
34 to hemorrhage. Patients who were able to walk < 48 hours after hospital admission
35
36 were considered to have independent ambulation at discharge.
37
38
39
40
41
42

43 **Statistical analysis**

44
45
46 Continuous variables were expressed as medians and interquartile ranges (IQR) and
47
48 categorical variables as frequencies and percentages. Between-group differences for
49
50 young vs. older adults were analyzed using the chi-square test, two sample t-test, or
51
52 corresponding nonparametric tests in cases of skewed distributions that cannot be
53
54 normalized. For outcomes such as IV tPA treatment and in-hospital outcomes, logistic
55
56 regression models were performed to determine adjusted odds ratios (aORs) and 95%
57
58
59
60

1
2
3
4 confidence intervals (CIs). Multivariate models were adjusted for gender, insurance
5
6 status, body mass index (BMI), medical history of prior stroke or transient ischemic
7
8 attack (TIA), coronary artery disease (CAD) or prior myocardial infarction (MI),
9
10 diabetes mellitus, hypertension, smoking status, atrial fibrillation/flutter, glycated
11
12 hemoglobin, diastolic blood pressure, systolic blood pressure, medication history
13
14 (hypoglycemic drugs, antihypertensive drugs, antiplatelet drugs, and lipid lowering
15
16 drugs), and hospital grade.
17
18
19
20
21
22
23
24

25
26 There were few missing data for most variables, with the exceptions of the in-hospital
27
28 NIHSS score (missing 19.4%), DNT (6.3%), glycated hemoglobin (10.6%) and BMI
29
30 (1.6%). For continuous variables missing less than 15%, the median was used for
31
32 imputation. Since the NIHSS score is a widely used tool for assessing stroke
33
34 severity[21] and contributes important information to AIS prognosis,[22] sensitivity
35
36 analyses adjusting for the NIHSS score were conducted. Because of the large sample
37
38 size, some statistically significant differences may not be clinically meaningful. We
39
40 used absolute standardized differences (ASD) to compare differences in baseline
41
42 characteristics between young and older adults independent of sample size. An ASD
43
44 larger than 10 was considered statistically significant.[23]
45
46
47
48
49
50
51
52
53
54

55 All statistical analyses were performed using SAS Version 9.4 (SAS Institute, Cary,
56
57 NC, USA) and the %ggBaseline SAS macro.[24] Two-sided p-values of <0.05 were
58
59
60

1
2
3
4 considered statistically significant.
5

6 **Patient and public involvement**

7
8
9 Patients or the public were not involved in the design, or conduct, or reporting, or
10
11
12 dissemination plans of our research.
13

14 **RESULTS**

15
16
17
18 Of 838 229 patients with AIS in the CSCA, 793 175 patients enrolled from 1471
19
20
21 hospitals were eligible for inclusion in this study. The median age was 67.0 years
22
23
24 (range: 58.0-75.0) and 62.7% were men. A total of 261 760 (33.0%) patients had
25
26
27 previous stroke/TIA, 69 810 (8.8%) had coronary artery disease or myocardial
28
29
30 infarction (CAD/prior MI), 170 638 (21.5%) had diabetes, 510 928 (64.4%) had
31
32
33 hypertension, 294 708 (37.2%) were smokers, and 40 231 (5.1%) had atrial
34
35
36 fibrillation/flutter.
37

38 **Clinical characteristics**

39
40 A total of 71 860 (9.1%) patients were young adults (<50 years) and 721 315 (90.9%)
41
42
43 were older adults (\geq 50 years). The median age among young adults was 45.0 (IQR
44
45
46 42.0-48.0) years and 68.0 (61.0-76.0) years among older adults. A larger proportion of
47
48
49 the young adults were men (76.3% vs 61.3%) and did not have health insurance
50
51
52 coverage (12.9% vs 5.7%), compared to older adults. Young adults had a lower
53
54
55 prevalence of cardiovascular risk factors compared to older adults, including history
56
57
58 of stroke or TIA (22.5% vs 34.0%), CAD/prior MI (4.0% vs 9.3%), diabetes mellitus
59
60
61 (15.3% vs 22.1%), hypertension (53.9% vs 65.5%), and atrial fibrillation (1.2% vs

5.5%). Young adults had a lower rate of medication use than older adults, including hypoglycemic drugs (10.9% vs 17.4%), antihypertensive drugs (33.5% vs 48%), antiplatelet drugs (14.6% vs 21.5%), and lipid lowering drugs (11.4% vs 15.3%). However, diastolic blood pressure in young adults was significantly higher than that of older adults (median 90.0, IQR 80.0-100.0 vs median 86.0, IQR 79.0-95.0), and young adults had a significantly higher mean BMI than older adults (median 24.2, IQR 22.6-26.4 vs median 23.7, IQR 21.7-25.4). The proportion of young adults who smoked was also higher than that of older adults (49.9% vs 35.9%) (Table 1).

Table 1. Baseline characteristics of young and old ischemic stroke patients

Baseline characteristics	Total (N=793175 [100%])	Young adults (< 50 years) (N=71860 [9.1%])	Old adults (≥50 years) (N=721315 [90.9%])	ASD*
Patient characteristics				
Age, years				
Mean±SD	66.1±12.0	43.8±5.3	68.3±10.0	306.1
Median (IQR)	67.0 (58.0–75.0)	45.0 (42.0–48.0)	68.0 (61.0–76.0)	
Male, n (%)	496960 (62.7)	54850 (76.3)	442110 (61.3)	32.8
Insurance status, n (%)				
UEBMI	225940 (28.5)	19160 (26.7)	206780 (28.7)	4.5
URBMI	149839 (18.9)	12393 (17.2)	137446 (19.1)	4.9
NRCMS	333979 (42.1)	27587 (38.4)	306392 (42.5)	8.4
Self-pa	50727 (6.4)	9263 (12.9)	41464 (5.7)	25.0
Other	32690 (4.1)	3457 (4.8)	29233 (4.1)	3.4
Arrive mode, n (%)				
Ambulance	89484 (11.3)	7170 (10.0)	82314 (11.4)	4.5
Private car	372727 (47.0)	33340 (46.4)	339387 (47.1)	1.4
Taxi	68801 (8.7)	6743 (9.4)	62058 (8.6)	2.8
Bicycle or tricycle	7237 (0.9)	577 (0.8)	6660 (0.9)	1.1
Helicopter	338 (0.0)	27 (0.0)	311 (0.0)	

1					
2					
3	Mobile stroke unit	246 (0.0)	24 (0.0)	222 (0.0)	
4	Other	254342 (32.1)	23979 (33.4)	230363 (31.9)	3.2
5					
6	Medical history, n (%)				
7	Previous stroke/TIA	261760 (33.0)	16197 (22.5)	245563 (34.0)	25.8
8	CAD/prior MI	69810 (8.8)	2906 (4.0)	66904 (9.3)	21.4
9	Diabetes	170638 (21.5)	10985 (15.3)	159653 (22.1)	17.5
10	Peripheral vascular disease	13512 (1.7)	718 (1.0)	12794 (1.8)	6.8
11	Hypertension	510928 (64.4)	38722 (53.9)	472206 (65.5)	23.8
12	Smoking [†]	294708 (37.2)	35848 (49.9)	258860 (35.9)	28.6
13	Atrial fibrillation/flutter	40231 (5.1)	886 (1.2)	39345 (5.5)	24.1
14	Dyslipidemia	60605 (7.6)	5861 (8.2)	54744 (7.6)	2.2
15	Carotid stenosis	10161 (1.3)	509 (0.7)	9652 (1.3)	6.0
16					
17	Medication history, n (%)				
18	Anticoagulants	31326 (3.9)	2394 (3.3)	28932 (4.0)	3.7
19	Hypoglycemic drugs	133244 (16.8)	7802 (10.9)	125442 (17.4)	18.7
20	Antihypertensive drugs	370017 (46.7)	24065 (33.5)	345952 (48.0)	29.8
21	Antiplatelet drugs	165771 (20.9)	10482 (14.6)	155289 (21.5)	18.0
22	Lipid lowering drugs	118827 (15.0)	8171 (11.4)	110656 (15.3)	11.5
23					
24	NIHSS score in hospital [‡]				
25	Mean±SD	4.8±5.2	4.0±4.5	4.9±5.3	18.3
26	Median (IQR)	3.0 (2.0–6.0)	3.0 (1.0–5.0)	3.0 (2.0–6.0)	
27					
28	Biochemical Indicators				
29	Glycated hemoglobin [§] , %				
30	Mean±SD	6.2±1.7	6.1±1.8	6.3±1.7	11.4
31	Median (IQR)	5.8 (5.3–6.5)	5.7 (5.2–6.1)	5.8 (5.3–6.5)	
32					
33	BMI				
34	Mean±SD	24.0±4.3	24.9±4.8	23.9±4.2	22.2
35	Median (IQR)	23.7 (21.9–25.5)	24.2 (22.6–26.4)	23.7 (21.7–25.4)	
36					
37	Homocysteine [#] , µmol/L				
38	Mean±SD	17.2±13.5	17.5±14.9	17.2±13.4	2.1
39	Median (IQR)	13.9 (10.4–19.1)	13.4 (10.0–19.0)	13.9 (10.5–19.1)	
40					
41	Systolic blood pressure ^{* *} , mmHg				
42	Mean±SD	150.0±23.0	147.9±24.4	150.2±22.8	9.7
43	Median (IQR)	150.0 (134.0–164.0)	145.0 (130.0–161.0)	150.0 (135.0–164.0)	
44					
45	Diastolic blood pressure ^{††} , mmHg				
46	Mean±SD	87.0±13.9	92.3±16.1	86.5±13.5	39.0
47	Median (IQR)	86.0 (79.0–96.0)	90.0 (80.0–100.0)	86.0 (79.0–95.0)	
48					
49	Hospital characteristics, n (%)				
50	Hospital level				
51					
52					
53					
54					
55					
56					
57					
58					
59					
60					

Secondary hospital	303790 (38.3)	23993 (33.4)	279797 (38.8)	11.3
Tertiary hospital	489385 (61.7)	47867 (66.6)	441518 (61.2)	11.3
Hospital region				
Eastern China	365579 (46.1)	32744 (45.6)	332835 (46.1)	1.0
Central China	262618 (33.1)	24477 (34.1)	238141 (33.0)	2.3
Western China	164978 (20.8)	14639 (20.4)	150339 (20.8)	1.0

Abbreviations: UEBMI, urban employee basic medical insurance; URBMI, urban resident basic medical insurance; NRCMS, new rural cooperative medical scheme; TIA,transient ischemic attack; CAD, coronary artery disease; MI, myocardial infarction; SD: standard deviation; IQR, interquartile range; NIHSS, National Institutes of Health Stroke Scale; ASD, absolute standardized difference.

*: An absolute standardized difference >10 indicates significant differences between 2 groups.

†: Smoking: having smoking experience or behaviors.

‡: Information was missing for N=154052 patients (19.4%).

§: Information was missing for N=84393 patients (10.6%); median was used for imputation.

||: Information was missing for N=12698 patients (1.6%); median was used for imputation..

#: Information was missing for N= 35781 patients (4.5%).

** : Information was missing for N=245 patients (≈0.0%); median was used for imputation.

††: Information was missing for N=251 patients (≈0.0%); median was used for imputation.

IV tPA treatment rates

Young adults were treated more frequently with IV tPA than older adults among patients without contraindications to thrombolysis (7.2% vs 6.1%, aOR 1.13, 95% CI 1.10-1.17) and among patients without contraindication and with onset-to-door time \leq 3.5h (23.6 % vs. 19.3%, aOR 1.20, 95% CI 1.15-1.24) . The adjusted OR of treatment with IV tPA was 1.20 (95% CI 1.16-1.24) or 1.24 (95% CI 1.20-1.29) in sensitivity analyses adjusting for NIHSS (Table 2).

Table 2. Multivariable analysis of IV tPA treatment by age group

Treatment	Total (N=793175 [100%])	Young adults (< 50 years) (N=71860 [9.1%])	Old adults (≥50 years) (N=721315 [90.9%])(REF)	Model	OR (95% CI)	P value
IV tPA among patients without contraindications	49456 (6.2)	5181 (7.2)	44275 (6.1)	1	1.19 (1.15-1.22)	<0.0001
				2	1.13 (1.10-1.17)	<0.0001

				3	1.20 (1.16-1.24)	<0.0001
IV tPA among patients without contraindication and with onset-to-door time ≤3.5h	45842 (19.7)	4768 (23.6)	41074 (19.3)	1	1.29 (1.25-1.34)	<0.0001
				2	1.20 (1.15-1.24)	<0.0001
				3	1.24 (1.20-1.29)	<0.0001

Abbreviations: CI, confidence interval; IV tPA, intravenous recombinant tissue plasminogen activator; OR, odds ratio.

Model 1: Logistic regression model without adjustment.

Model 2: adjusted for gender, insurance, BMI, previous stroke/TIA, previous CAD/prior MI, diabetes, hypertension, have smoking experience or behavior, atrial fibrillation/flutter, glycated, hemoglobin, diastolic blood pressure, hypoglycemic drugs, antihypertensive drugs, antiplatelet drugs, lipid-lowering drugs, and hospital level.

Model 3: adjusted for were in-hospital NIHSS score, gender, insurance, BMI, previous stroke/TIA, previous CAD/prior MI, diabetes, hypertension, have smoking experience or behavior, atrial fibrillation/flutter, glycated hemoglobin, diastolic blood pressure, hypoglycemic drugs, antihypertensive drugs, antiplatelet drugs, lipid-lowering drugs, and hospital level. Patients (N= 154052) with missing values on NIHSS score were not included in this analysis.

Treatment time

While young adults were more likely to receive IV tPA, there was no significant difference in onset-to-needle time (median 2.7 hours, IQR 2.0–3.5 for both groups) and DNT (median 60.0 minutes, IQR 42.0-90.0 vs median 60.0 minutes, IQR 36.0-84.0) among young and older adults. DNT was also analyzed as a binary outcome at three levels: DNT ≤30, DNT ≤45, and DNT ≤60 minutes. There were no significant differences between the two groups on any DNT level (16.9% vs 18.8%; 30.2% vs 32.8%; 50.2% vs 54.2%) (Table 3).

Table 3. Treatment time in young and old ischemic stroke patients treated with IV tPA

Measures	Total (N=48141 [100%])	Young adults (< 50 years) (N=5044 [10.5%])	Old adults (≥50 years) (N=43097 [89.5%])	ASD*
----------	---------------------------	--	--	------

Onset-to-needle time [†] ,h				
Median (IQR)	2.7 (2.0–3.5)	2.7 (2.0–3.5)	2.7 (2.0–3.5)	
DNT [‡] ,min				
Mean±SD	66.8±44.1	70.8±46.8	66.4±43.8	9.7
Median (IQR)	60.0 (36.0–84.0)	60.0 (42.0–90.0)	60.0 (36.0–84.0)	
Treatment time				
DNT≤30 minutes	8938 (18.6)	850 (16.9)	8088 (18.8)	5.0
DNT≤45 minutes	15637 (32.5)	1521 (30.2)	14116 (32.8)	5.6
DNT≤60 minutes	25884 (53.8)	2531 (50.2)	23353 (54.2)	8.0

Abbreviations: CI=confidence interval; IV tPA, intravenous recombinant tissue plasminogen activator; DNT, door-to-needle time ; ASD, absolute standardized difference.

*:An absolute standardized difference >10 indicates significant differences between 2 groups.

[†]: Onset-to-needle time was missing for 3818(7.9%) patients, with 431(8.5%) in age <50 and 3387(7.9%) in ≥ 50 groups.

[‡]DNT was missing for 3027(6.3%) patients, with 342 (6.8%) in age <50 and 2685(6.2%) in ≥ 50 groups.

In-hospital outcomes

In-hospital outcomes including sICH, in-hospital mortality, and independent ambulation at discharge were summarized in Table 4. Multiple logistic regression with adjustments of unbalanced covariates (ASD>10% in Supplemental Table I) showed that young adults had non-significantly lower rates of sICH (0.5% vs 0.9%, aOR=0.74, 95%CI 0.49-1.11) than older adults. However, young adults had significantly lower rates of in-hospital mortality (0.5% vs 1.3%, aOR=0.54, 95%CI 0.35-0.82) and were more likely to be independently ambulating at discharge (61.0% vs 53.6%, aOR=1.15, 95%CI 1.08-1.22).

In sensitivity analyses adjusted for NIHSS scores, young adults had non-significantly lower odds of sICH (aOR=0.77, 95%CI 0.5-1.18), in-hospital mortality (aOR=0.70, 95%CI 0.46-1.09), and non-significantly higher odds of independent ambulation at

1
2
3
4 discharge (aOR=1.00, 95%CI 0.93-1.08). Sensitivity analysis using different age
5
6 cut-off point(<35 years and \geq 35 years) showed consistent results with primary
7
8 analysis (supplemental material table II). But when we used another age cut of point
9
10 (<45 years and \geq 45 years), we had a lower sICH rate (aOR=0.44, 95%CI 0.19-0.99)
11
12
13
14
15 in the young group (supplemental material table III).
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Table 4. In-hospital outcomes in young and old ischemic stroke patients treated with IV tPA

Outcome	Total (N=48141 [100%])	Young adults (< 50 years) (N=5044 [10.5%])	Old adults (≥50 years) (N=43097 [89.5%])(REF)	Model	OR (95% CI)	P value
sICH	414 (0.9)	26 (0.5)	388 (0.9)	1	0.57 (0.38-0.85)	0.0057
				2	0.74 (0.49-1.11)	0.1446
				3	0.77 (0.5-1.18)	0.2277
In-hospital mortality	579 (1.2)	24 (0.5)	555 (1.3)	1	0.37 (0.24-0.55)	<0.0001
				2	0.54 (0.35-0.82)	0.0037
				3	0.70 (0.46-1.09)	0.1140
Independent ambulation at discharge	26175 (54.4)	3079 (61.0)	23096 (53.6)	1	1.36 (1.28-1.44)	<0.0001
				2	1.15 (1.08-1.22)	<0.0001
				3	1.00 (0.93-1.08)	0.9490

Abbreviations: CI, confidence interval; IV tPA, intravenous recombinant tissue plasminogen activator ; OR, odds ratio.

Model 1: Logistic regression model without adjustment.

Model 2: Adjusted for gender, insurance, BMI, previous stroke/TIA, previous CAD/prior MI, diabetes, hypertension, have smoking experience or behavior, atrial fibrillation/flutter, glycated hemoglobin, diastolic blood pressure, systolic blood pressure, hypoglycemic drugs, antihypertensive drugs, antiplatelet drugs, and lipid-lowering drugs.

Model 3: Adjusted for in-hospital NIHSS score, gender, insurance, BMI, previous stroke/TIA, previous CAD/prior MI, diabetes, hypertension, have smoking experience or behavior, atrial fibrillation/flutter, glycated hemoglobin, diastolic blood pressure, blood pressure, hypoglycemic drugs, antihypertensive drugs, antiplatelet drugs, and lipid-lowering drugs. Patients (N= 2503) with missing values on NIHSS score were not included in this analysis.

DISCUSSION

In this hospital-based observational study of 793 175 AIS patients, we found that young adults (<50 years of age) were more likely to be treated with IV tPA than older adults (7.2% vs 6.1%), which was consistent with our hypothesis. Our study demonstrated that young stroke patients had fewer comorbidities (previous stroke/TIA, previous CAD/prior MI, diabetes, hypertension, and atrial fibrillation/flutter) at baseline, which may compel providers to feel more secure in administering IV tPA to this group of patients. Even though we did not observe a difference in DNT between age groups, we found that young adults had more favorable in-hospital outcomes than older adults, including lower odds of sICH, in-hospital mortality and higher odds of independent ambulation at discharge, but adjusted for NIHSS scores, the results were not significant, so the associations may be explained by stroke severity measured by NIHSS score.

IV tPA thrombolytic therapy is considered to be the standard therapy in patients with acute ischemic stroke. However, its use has been studied primarily in adults over age 50.[16] Given increasing evidence in the literature that thrombolytic therapy rarely causes hemorrhages in patients with stroke-mimicking conditions, providers may also feel more comfortable administering IV tPA to young adults when it is uncertain whether a stroke or a stroke mimic had occurred.[25] Our research also supports this conclusion. Young adults had similar time to treatment and were more likely to be

1
2
3
4 treated than older adults, which may reflect increased awareness among patients and
5
6
7 clinicians that stroke is a potentially fatal disease affecting people of all ages.

8
9 The relationship between time to treatment and mortality was first recognized in
10
11
12 clinical studies.[26,27] The importance of this metric was reemphasized in the 2004
13
14
15 American College of Cardiology/American Heart Association practice guidelines,
16
17
18 which stated that DNT targets “should not be perceived as an average performance
19
20
21 standard but as a goal that an early treatment system in every hospital should seek for
22
23
24 every appropriate patient”. [28] Consistent with a prior analysis of SITS-ISTR
25
26
27 showing no difference in median door-to-needle times between patients 18 to 50
28
29
30 and >50 years of age, there was also not an obvious differentiation in treatment
31
32
33 among young or older adults in our study.[15] However, a prior study by Dodds and
34
35
36 colleagues found that young adults (18-40 years) with AIS were more likely to
37
38
39 experience a delay in evaluation and treatment.[12] Our definition of young adults
40
41
42 (age <50 years) differs from theirs (age 18–40 years) and is more applicable in China,
43
44
45 which may also explain why we did not find differences in treatment times between
46
47
48 the two groups.[29] Another explanation for the lack of differences in treatment times
49
50
51 between the two groups may be that DNT mainly depends on hospital level and
52
53
54 treatment process rather than age.

55
56
57 In our study, we observed a higher rate of sICH and in-hospital mortality among older
58
59
60 adults treated with IV tPA, though the difference was not significant adjusted for
NIHSS scores. We cannot entirely separate young age from lower NIHSS score, as

1
2
3
4 young patients are highly correlated with lower NIHSS scores in clinical practise
5
6 (4.0±4.5 vs. 4.9±5.3, the Rank Biserial correlation coefficient in this study is 0.10,
7
8 p<0.001). Therefore, the associations may be partly explained by stroke severity
9
10 measured by NIHSS score. A Canadian study found that the sICH proportion among
11
12 younger patients did not differ from those over 50 (3% vs 4.7%, p=0.62).[16] Our
13
14 finding is consistent with the results of this study. But in two other studies, however,
15
16 younger patients treated with tPA had a lower sICH rate.[13,15] Although we do not
17
18 find significant differences between these two groups, we do see a trend towards
19
20 better outcomes in young people. One possible explanation is that younger stroke
21
22 patients have fewer comorbidities in their medical history, such as previous stroke or
23
24 TIA, CAD/MI, diabetes mellitus, hypertension, and atrial fibrillation, as well as
25
26 milder strokes, all of which are associated with better outcomes.[30] Other factors
27
28 favoring recovery in young stroke patients include greater brain plasticity and more
29
30 robust family and social support.[31] There could be several reasons why we didn't
31
32 reach the same conclusion as the two studies. Firstly, the GWTG-Stroke study had a
33
34 much larger sample size and used age<40 to define young adults, while the
35
36 SITS-ISTR study had a much higher NIHSS score and a different definition for sICH.
37
38 [13,15] When we used different age cut of point (<45 years and ≥45 years), we had
39
40 a lower sICH rate (aOR=0.44, 95%CI 0.19-0.99) in the young group (supplemental
41
42 material table III). Secondly, this may also reflect, in part, that physicians in China
43
44 are more conservative in selecting patients for intravenous thrombolysis because of
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 possible complications. There are several limitations in our study. Since hospital
5
6 participation in the CSCA is voluntary, participating hospitals are more likely to be
7
8 larger, tertiary centers with a myriad of resources that smaller hospitals do not have
9
10 access to. We recognize that findings from CSCA may not be generalizable to AIS
11
12 patients admitted to hospitals outside of the CSCA. Second, we did not report data on
13
14 intra-arterial (IA) therapies and puncture times because only a very small number of
15
16 patients in our study received thrombectomy. We also did not have door-to-imaging
17
18 data to support the study and there was a relatively high proportion of missing DNT
19
20 values (6.3% overall, 6.8% in young and 6.2% in older patients). However, we did not
21
22 observe a significant difference in DNTs between young and older AIS patients.
23
24 Lastly, we cannot entirely separate young age from lower NIHSS score, as younger
25
26 age is inherently correlated with a lower NIHSS score. Therefore, better prognosis can
27
28 not be fully attributed to NIHSS score nor age. But this is a real world study, which
29
30 represent the current situation of thrombolysis in China. It is based on these data that
31
32 we are constantly improving the process and quality of thrombolysis.
33
34
35
36
37
38
39
40
41
42
43
44

45 CONCLUSION

46
47
48 In summary, young adults with AIS are more likely to receive IV tPA than older
49
50 adults, but there is no difference between the two groups in time to treatment. Young
51
52 adults may have better in-hospital outcomes compared with older adults, suggesting
53
54 favorable effects of treatment with IV tPA.
55
56
57
58
59
60

ACKNOWLEDGEMENTS

We thank the staff and participants of the CSCA (Chinese Stroke Center Alliance) studies for their contribution.

CONTRIBUTORS

Conceived and led the project: XZ, YW, ZL, YW and YJ. Conception and design:

HW, HG, YW and YJ. Data collection and analysis: HW, XY, CW, HG and QZ.

Interpret the data: LL, XM and HL. Drafting the article and revising the content: HW,

HG, CL, JY and ZL. All authors approved the final version of the manuscript.

FUNDING

The Chinese Stroke Center Alliance program was supported by grants from the Ministry of Science and Technology and the Ministry of Health of the People's Republic of China (National Key R&D Program of China, Code: 2016YFC0901001, 2017YFC1310901, 2016YFC0901002, 2017YFC1307905, 2015BAI12B00), Beijing Talents Project (2018A13, 2018000021223ZK03), CAMS Innovation Fund for Medical Sciences (2019-I2M-5-029), Beijing Municipal Committee of Science and Technology (Z201100005620010), Beijing Natural Science Foundation (Z200016).

COMPETING INTERESTS

1
2
3 None declared.
4
5
6
7

8 **PATIENT CONSENT FOR PUBLICATION**

9

10 Not required.
11
12
13
14

15 **ETHICS APPROVAL**

16

17
18 This study received approval from the Institutional Review Board/Ethics Committee
19 of Beijing Tiantan Hospital, Capital Medical University with approval number KY
20
21 2018-061-02. Participating hospitals received research approval to collect data in
22
23 CSCA without requiring individual patient informed consent under the common rule
24
25 or a waiver of authorisation and exemption from their Institutional Review Board.
26
27
28
29
30
31
32
33
34

35 **REFERENCES**

36
37
38

- 39 1. Béjot Y, Bailly H, Durier J, et al. Epidemiology of stroke in Europe and trends for
40 the 21st century. *Presse Med* 2016;45:e391-8. doi: 10.1016/j.lpm.2016.10.003
41
42 [published Online First: 2016/11/07]
43
44
45
46 2. Hathidara MY, Saini V, Malik AM. Stroke in the young: A global update. *Current*
47
48 *neurology and neuroscience reports* 2019;19:91. doi: 10.1007/s11910-019-1004-1
49
50 [published Online First: 2019/11/27]
51
52
53
54 3. Rutten-Jacobs LC, Maaijwee NA, Arntz RM, et al. Risk factors and prognosis of
55
56 young stroke. The FUTURE study: a prospective cohort study. Study rationale and
57
58
59
60

1
2
3
4 protocol. *BMC Neurol* 2011;11:109. doi: 10.1186/1471-2377-11-109 [published
5
6
7 Online First: 2011/09/22]

8
9 4. George MG. Risk Factors for Ischemic Stroke in Younger Adults: A Focused
10
11
12 Update. *Stroke* 2020;51:729-35. doi: 10.1161/strokeaha.119.024156 [published
13
14
15 Online First: 2020/02/23]

16
17 5. Maaijwee NA, Rutten-Jacobs LC, Schaapsmeeders P, et al. Ischaemic stroke in
18
19
20 young adults: risk factors and long-term consequences. *Nat Rev Neurol*
21
22
23 2014;10:315-25. doi: 10.1038/nrneurol.2014.72 [published Online First: 2014/04/30]

24
25 6. Feigin VL, Roth GA, Naghavi M, et al. Global burden of stroke and risk factors in
26
27
28 188 countries, during 1990–2013: a systematic analysis for the Global Burden of
29
30
31 Disease Study 2013. *The Lancet Neurology* 2016;15:913-24. doi:
32
33
34 10.1016/s1474-4422(16)30073-4

35
36 7. Wang Y-J, Li Z-X, Gu H-Q, et al. China Stroke Statistics 2019: A Report From the
37
38
39 National Center for Healthcare Quality Management in Neurological Diseases, China
40
41
42 National Clinical Research Center for Neurological Diseases, the Chinese Stroke
43
44
45 Association, National Center for Chronic and Non-communicable Disease Control
46
47
48 and Prevention, Chinese Center for Disease Control and Prevention and Institute for
49
50
51 Global Neuroscience and Stroke Collaborations. *Stroke and Vascular Neurology*
52
53
54 2020;5:211-39. doi: 10.1136/svn-2020-000457

55
56 8. Singhal AB, Biller J, Elkind MS, et al. Recognition and management of stroke in
57
58
59 young adults and adolescents. *Neurology* 2013;81:1089-97. doi:
60

- 1
2
3
4 10.1212/WNL.0b013e3182a4a451 [published Online First: 2013/08/16]
5
6
7 9. Peña-Martínez C, Durán-Laforet V, García-Culebras A, et al. Pharmacological
8
9 Modulation of Neutrophil Extracellular Traps Reverses Thrombotic Stroke tPA
10
11 (Tissue-Type Plasminogen Activator) Resistance. *Stroke* 2019;50:3228-37. doi:
12
13 10.1161/strokeaha.119.026848 [published Online First: 2019/09/19]
14
15 10.1161/strokeaha.119.026848 [published Online First: 2019/09/19]
16
17 10. Martínez-Sánchez P, Díez-Tejedor E, Fuentes B, et al. Systemic Reperfusion
18
19 Therapy in Acute Ischemic Stroke. *Cerebrovascular Diseases* 2007;24:143-52. doi:
20
21 10.1159/000107390
22
23 10.1159/000107390
24
25 11. Tomsick TA. Intravenous thrombolysis for acute ischemic stroke. *J Vasc Interv*
26
27 *Radiol* 2004;15:S67-76. doi: 10.1097/01.rvi.0000109203.06450.e3 [published Online
28
29 First: 2004/04/27]
30
31
32
33 12. Kim JT, Fonarow GC, Smith EE, et al. Treatment With Tissue Plasminogen
34
35 Activator in the Golden Hour and the Shape of the 4.5-Hour Time-Benefit Curve in
36
37 the National United States Get With The Guidelines-Stroke Population. *Circulation*
38
39 2017;135:128-39. doi: 10.1161/circulationaha.116.023336 [published Online First:
40
41 2016/11/07]
42
43
44
45 13. Dodds JA, Xian Y, Sheng S, et al. Thrombolysis in young adults with stroke:
46
47 Findings from Get With The Guidelines-Stroke. *Neurology* 2019;92:e2784-92. doi:
48
49 10.1212/wnl.00000000000007653 [published Online First: 2019/05/17]
50
51
52
53 14. Papavasileiou V, Goldstein LB. Thrombolysis in young adults with acute ischemic
54
55 stroke. *Neurology* 2019;92:1129-30. doi: 10.1212/wnl.00000000000007651
56
57
58
59
60

- 1
2
3
4 15. Toni D, Ahmed N, Anzini A, et al. Intravenous thrombolysis in young stroke
5
6 patients: results from the SITS-ISTR. *Neurology* 2012;78:880-7. doi:
7
8 10.1212/WNL.0b013e31824d966b [published Online First: 2012/03/10]
9
10
11
12 16. Poppe AY, Buchan AM, Hill MD. Intravenous thrombolysis for acute ischaemic
13
14 stroke in young adult patients. *Can J Neurol Sci* 2009;36:161-7. doi:
15
16 10.1017/s031716710012027x [published Online First: 2009/04/22]
17
18
19
20 17. Shi J, Cao Y, You S, et al. Young Stroke Patients Treated with Intravenous
21
22 Thrombolysis have a More Favorable Outcome and Mortality Compared with Older
23
24 Patients. *Curr Neurovasc Res* 2017;14:141-48. doi:
25
26 10.2174/1567202614666170328095431 [published Online First: 2017/03/31]
27
28
29
30 18. Wang Y, Li Z, Wang Y, et al. Chinese Stroke Center Alliance: a national effort to
31
32 improve healthcare quality for acute stroke and transient ischaemic attack: rationale,
33
34 design and preliminary findings. *Stroke Vasc Neurol* 2018;3:256-62. doi:
35
36 10.1136/svn-2018-000154 [published Online First: 2019/01/15]
37
38
39
40 19. Hsieh CY, Chen WF, Chen CH, et al. Efforts to reduce the door-to-needle time of
41
42 thrombolysis in acute ischemic stroke: video-assisted therapeutic risk communication.
43
44 *J Formos Med Assoc* 2014;113:929-33. doi: 10.1016/j.jfma.2013.11.012 [published
45
46 Online First: 2014/01/15]
47
48
49
50 20. van Tuijn CF, Luitse JS, van der Valk M, et al. Reduction of the door-to-needle
51
52 time for administration of antibiotics in patients with a severe infection: a tailored
53
54 intervention project. *Neth J Med* 2010;68:123-7.
55
56
57
58
59
60

- 1
2
3
4 21. Habib M, Karim ASMR, Hossain MM, et al. Assessment of Initial Stroke Severity
5
6 by National Institute Health Stroke Scale (NIHSS) Score at Admission. *Journal of*
7
8 *Dhaka Medical College* 2018;26:90-93. doi: 10.3329/jdmc.v26i2.38765
9
10
11
12 22. Chen X, Zhan X, Chen M, et al. The prognostic value of combined NT-pro-BNP
13
14 levels and NIHSS scores in patients with acute ischemic stroke. *Intern Med*
15
16 2012;51:2887-92. doi: 10.2169/internalmedicine.51.8027 [published Online First:
17
18 2012/10/16]
19
20
21
22
23 23. Austin PC. Balance diagnostics for comparing the distribution of baseline
24
25 covariates between treatment groups in propensity-score matched samples. *Stat Med*
26
27 2009;28:3083-107. doi: 10.1002/sim.3697 [published Online First: 2009/09/17]
28
29
30
31 24. Gu HQ, Li DJ, Liu C, et al. %ggBaseline: a SAS macro for analyzing and
32
33 reporting baseline characteristics automatically in medical research. *Ann Transl Med*
34
35 2018;6:326. doi: 10.21037/atm.2018.08.13 [published Online First: 2018/10/27]
36
37
38
39 25. Zinkstok SM, Engelter ST, Gensicke H, et al. Safety of thrombolysis in stroke
40
41 mimics: results from a multicenter cohort study. *Stroke* 2013;44:1080-4. doi:
42
43 10.1161/STROKEAHA.111.000126
44
45
46
47 26. Cannon CP, Gibson CM, Lambrew CT, et al. Relationship of
48
49 symptom-onset-to-balloon time and door-to-balloon time with mortality in patients
50
51 undergoing angioplasty for acute myocardial infarction. *Jama* 2000;283:2941-7. doi:
52
53 10.1001/jama.283.22.2941 [published Online First: 2000/06/24]
54
55
56
57
58 27. Schull MJ, Vermeulen M, Donovan L, et al. Can the wrong statistic be bad for
59
60

1
2
3
4 health? Improving the reporting of door-to-needle time performance in acute
5
6 myocardial infarction. *Am Heart J* 2005;150:583-7. doi: 10.1016/j.ahj.2005.03.061

7
8
9 [published Online First: 2005/09/20]

10
11
12 28. Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the
13
14 management of patients with ST-elevation myocardial infarction--executive summary:
15
16 a report of the American College of Cardiology/American Heart Association Task
17
18 Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for
19
20 the Management of Patients With Acute Myocardial Infarction). *Circulation*
21
22 2004;110:588-636. doi: 10.1161/01.Cir.0000134791.68010.Fa [published Online First:
23
24 2004/08/04]

25
26 29. Xiaobing Z SH, Li'an H. Clinical investigation of stroke in young and
27
28 middle-aged adults. *Cerebrovascular Diseases Foreign Medical Sciences*
29
30 2004;012:354-7.

31
32 30. Arnold M, Halpern M, Meier N, et al. Age-dependent differences in demographics,
33
34 risk factors, co-morbidity, etiology, management, and clinical outcome of acute
35
36 ischemic stroke. *Journal of Neurology* 2008;255:1503-07. doi:
37
38 10.1007/s00415-008-0949-9

39
40 31. Popa-Wagner A, Carmichael ST, Kokaia Z, et al. The response of the aged brain
41
42 to stroke: too much, too soon? *Curr Neurovasc Res* 2007;4:216-27. doi:
43
44 10.2174/156720207781387213 [published Online First: 2007/08/19]

45
46
47
48
49
50
51
52
53
54
55
56
57
58
59 **Figure legend**
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 1. Study flowchart for patients identification.

Abbreviations: IV tPA, intravenous tissue plasminogen activator.

For peer review only

Source population

Admission (N=838229)
Hospital (N=1473)
August 1, 2015 to July 31, 2019

Excluded (n=45054)

- In-hospital stroke (7941)
- Missing IV tPA information (17461)
- Missing arrival time (12)
- Transferred in from acute care hospital (1777)
- Contraindications to venous thrombolysis within a time window (17863)

Analysis of outcomes in all ischemic stroke

Admission (N=793175)
Hospital (N=1471)

Excluding (n=745034)

- Treated with tPA but >4.5h (1315) Not
- treated with tPA (743719)

Analysis of treatment times, and outcomes in patients treated with tPA within 4.5 hours

Admission (N=48141)
Hospital (N=1290)

Supplemental Material

1

2

3 Table I . Baseline characteristics of young and old ischemic stroke patients with IV tPA treatment

4

5 Baseline characteristics	Total (N=48141 [100%])	Young adults (< 50 years) (N=5044 [10.5%])	Old adults (≥50 years) (N=43097 [89.5%])	ASD*
8 Patient characteristics				
9 Age, years				
10 Mean±SD	65.2±12.1	43.4±5.6	67.8±9.8	305.7
11 Median (IQR)	66.0 (57.0–74.0)	45.0 (41.0–48.0)	68.0 (60.0–75.0)	
12 Male, n (%)	31456 (65.3)	3961 (78.5)	27495 (63.8)	32.9
13 Insurance status, n (%)				
14 UEBMI	15948 (33.1)	1609 (31.9)	14339 (33.3)	3.0
15 URBMI	9813 (20.4)	913 (18.1)	8900 (20.7)	6.6
16 NRCMS	16442 (34.2)	1495 (29.6)	14947 (34.7)	10.9
17 Self-pa	4083 (8.5)	813 (16.1)	3270 (7.6)	26.5
18 Other	1855 (3.9)	214 (4.2)	1641 (3.8)	2.0
19 Arrive mode, n (%)				
20 Ambulance	14364 (29.8)	1352 (26.8)	13012 (30.2)	7.5
21 Private car	21213 (44.1)	2240 (44.4)	18973 (44.0)	0.8
22 Taxi	2539 (5.3)	357 (7.1)	2182 (5.1)	8.4
23 Bicycle or tricycle	118 (0.2)	7 (0.1)	111 (0.3)	4.5
24 Helicopter	14 (0.0)	1 (0.0)	13 (0.0)	
25 Mobile stroke unit	31 (0.1)	4 (0.1)	27 (0.1)	0.0
26 Other	9862 (20.5)	1083 (21.5)	8779 (20.4)	2.7
27 Medical history, n (%)				
28 Previous stroke/TIA	12339 (25.6)	830 (16.5)	11509 (26.7)	25.0
29 CAD/prior MI	4737 (9.8)	240 (4.8)	4497 (10.4)	21.3
30 Diabetes	8477 (17.6)	516 (10.2)	7961 (18.5)	23.8
31 Peripheral vascular disease	628 (1.3)	31 (0.6)	597 (1.4)	8.0
32 Hypertension	28815 (59.9)	2283 (45.3)	26532 (61.6)	33.1
33 Smoking†	18835 (39.1)	2567 (50.9)	16268 (37.7)	26.8
34 Atrial fibrillation/flutter	5692 (11.8)	138 (2.7)	5554 (12.9)	38.7
35 Dyslipidemia	3195 (6.6)	351 (7.0)	2844 (6.6)	1.6
36 Carotid stenosis	454 (0.9)	22 (0.4)	432 (1.0)	7.2
37 Medication history, n (%)				
38 Anticoagulants	1779 (3.7)	150 (3.0)	1629 (3.8)	4.4
39 Hypoglycemic drugs	6404 (13.3)	330 (6.5)	6074 (14.1)	25.2
40 Antihypertensive drugs	20099 (41.8)	1302 (25.8)	18797 (43.6)	38.1
41 Antiplatelet drugs	7882 (16.4)	467 (9.3)	7415 (17.2)	23.5
42 Lipid lowering drugs	5614 (11.7)	382 (7.6)	5232 (12.1)	15.1
43 NIHSS score in hospital‡				
44 Mean±SD	7.9±6.5	6.4±5.3	8.0±6.6	26.7
45 Median (IQR)	6.0 (3.0–11.0)	5.0 (3.0–9.0)	6.0 (3.0–12.0)	

60

(Continued)

Table I . Baseline characteristics of young and old ischemic stroke patients with IV tPA treatment

Baseline characteristics	Total (N=48141 [100%])	Young adults (< 50 years) (N=5044 [10.5%])	Old adults (≥50 years) (N=43097 [89.5%])	ASD*
Biochemical Indicators				
Glycated hemoglobins,%				
Mean±SD	6.2±1.6	5.9±1.5	6.2±1.6	19.3
Median (IQR)	5.8 (5.3–6.4)	5.6 (5.1–6.0)	5.8 (5.3–6.5)	
BMI				
Mean±SD	23.6±4.2	24.9±5.5	23.4±4.0	31.2
Median (IQR)	23.4 (21.1–25.5)	24.4 (22.3–26.8)	23.2 (21.0–25.4)	
Homocysteine [#] , μmol/L				
Mean±SD	16.7±13.1	17.4±14.8	16.6±12.9	5.8
Median (IQR)	13.3 (10.0–18.5)	12.7 (9.6–18.9)	13.3 (10.1–18.5)	
Systolic blood pressure** , mmHg				
Mean±SD	152.5±23.8	148.3±24.6	153.0±23.7	19.5
Median (IQR)	150.0 (136.0–168.0)	145.0 (130.0–163.0)	151.0 (137.0–168.0)	
Diastolic blood pressure ^{††} , mmHg				
Mean±SD	87.6±14.5	92.1±16.1	87.1±14.2	32.9
Median (IQR)	87.0 (79.0–97.0)	90.0 (80.0–101.0)	86.0 (78.0–96.0)	
Hospital characteristics, n (%)				
Hospital level				
Secondary hospital	16479 (34.2)	1735 (34.4)	14744 (34.2)	0.4
Tertiary hospital	31662 (65.8)	3309 (65.6)	28353 (65.8)	0.4
Hospital region				
Eastern China	26410 (54.9)	2792 (55.4)	23618 (54.8)	1.2
Central China	15024 (31.2)	1630 (32.3)	13394 (31.1)	2.6
Western China	6707 (13.9)	622 (12.3)	6085 (14.1)	5.3

Abbreviations: IV tPA, intravenous recombinant tissue plasminogen activator; UEBMI, urban employee basic medical insurance; URBMI, urban resident basic medical insurance; NRCMS, new rural cooperative medical scheme; TIA, transient ischemic attack; CAD, coronary artery disease; MI, myocardial infarction; SD: standard deviation; IQR, interquartile range; NIHSS, National Institutes of Health Stroke Scale; ASD, absolute standardized difference.

*: An absolute standardized difference >10 indicates significant differences between 2 groups.

†: Smoking: having smoking experience or behaviors.

†: Information was missing for N = 2503 patients (5.2%).

§: Information was missing for N =4749 patients (9.9%), using the median for imputation.

||: Information was missing for N =743 patients (1.5%), using the median for imputation.

#: Information was missing for N = 2682 patients (5.6%).

** : Information was missing for N =28 patients (0.1 %), using the median for imputation.

††: Information was missing for N =28 patients (0.1%), using the median for imputation.

Table II . In-hospital outcomes in young(< 35 years) and old (≥35 years) ischemic stroke patients treated with IV tPA

Outcome	Total (N=48141 [100%])	young adults (< 35 years) (N=456 [0.9%])	old adults (≥35 years) (N=47685[99.1%])(REF)	Model	OR (95% CI)	P value
sICH	414 (0.9)	4 (0.9)	410 (0.9)	1	1.02 (0.38-2.74)	0.9678
				2	1.45 (0.54-3.94)	0.4612
				3	1.52 (0.56-4.13)	0.4136
In-hospital mortality	579 (1.2)	1 (0.2)	578 (1.2)	1	0.18 (0.03-1.28)	0.0861
				2	0.28 (0.04-2.01)	0.2066
				3	0.27 (0.04-1.97)	0.1953
Independent ambulation at discharge	26175 (54.4)	279 (61.2)	25896 (54.3)	1	1.33 (1.10-1.60)	0.0034
				2	1.09 (0.90-1.32)	0.384
				3	1.15 (0.92-1.42)	0.2173

Abbreviations: CI, confidence interval; IV tPA, intravenous recombinant tissue plasminogen activator ; OR, odds ratio.

Model 1: Logistic regression model without adjustment.

Model 2: Adjusted for gender, insurance, BMI, previous stroke/TIA, previous CAD/prior MI, diabetes, hypertension, have smoking experience or behavior, atrial fibrillation/flutter, glyated hemoglobin, diastolic blood pressure, systolic blood pressure, hypoglycemic drugs, antihypertensive drugs, antiplatelet drugs,and lipid-lowering drugs.

Model 3: Adjusted for in-hospital NIHSS score, gender, insurance, BMI, previous stroke/TIA, previous CAD/prior MI, diabetes, hypertension, have smoking experience or behavior, atrial fibrillation/flutter, glyated hemoglobin, diastolic blood pressure, blood pressure, hypoglycemic drugs, antihypertensive drugs, antiplatelet drugs, and lipid-lowering drugs. Patients (N= 2503) with missing values on NIHSS score were not included in this analysis.

Table III. In-hospital outcomes in young (< 45 years) and old (≥45 years) ischemic stroke patients treated with IV tPA

Outcome	Total (N=48141 [100%])	young adults (< 45 years) (N=2244 [4.7%])	old adults (≥45 years) (N=45897[95.3%])(REF)	Model	OR (95% CI)	P value
sICH	414 (0.9)	8 (0.4)	406 (0.9)	1	0.40 (0.20-0.81)	0.0106
				2	0.54 (0.26-1.10)	0.0877
				3	0.44 (0.19-0.99)	0.048
In-hospital mortality	579 (1.2)	8 (0.4)	571 (1.2)	1	0.28 (0.14-0.57)	0.0004
				2	0.43 (0.21-0.87)	0.0197
				3	0.52 (0.26-1.07)	0.077
Independent ambulation at discharge	26175 (54.4)	1356 (60.4)	24819 (54.1)	1	1.30 (1.19-1.41)	<0.0001
				2	1.08 (0.98-1.18)	0.1082
				3	0.97 (0.88-1.08)	0.6096

Abbreviations: CI, confidence interval; IV tPA, intravenous recombinant tissue plasminogen activator ; OR, odds ratio.

Model 1: Logistic regression model without adjustment.

Model 2: Adjusted for gender, insurance, BMI, previous stroke/TIA, previous CAD/prior MI, diabetes, hypertension, have smoking experience or behavior, atrial fibrillation/flutter, glyated hemoglobin, diastolic blood pressure, systolic blood pressure, hypoglycemic drugs, antihypertensive drugs, antiplatelet drugs, and lipid-lowering drugs.

Model 3: Adjusted for in-hospital NIHSS score, gender, insurance, BMI, previous stroke/TIA, previous CAD/prior MI, diabetes, hypertension, have smoking experience or behavior, atrial fibrillation/flutter, glyated hemoglobin, diastolic blood pressure, blood pressure, hypoglycemic drugs, antihypertensive drugs, antiplatelet drugs, and lipid-lowering drugs. Patients (N= 2503) with missing values on NIHSS score were not included in this analysis.

BMJ Open

Thrombolysis, Time-to-Treatment and In-Hospital Outcomes Among Young Adults with Ischemic Stroke in China: Findings from a Nationwide Registry Study in China

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-055055.R1
Article Type:	Original research
Date Submitted by the Author:	20-Jan-2022
Complete List of Authors:	<p>Wang, HaiYan; Capital Medical University Affiliated Beijing Shijitan Hospital, Department of Neurology</p> <p>Gu, Hongqiu; Beijing Tiantan Hospital, China National Clinical Research Center for Neurological Diseases; Beijing Tiantan Hospital, National Center for Healthcare Quality Management in Neurological Diseases</p> <p>Zhou, Qi; Beijing Tiantan Hospital, China National Clinical Research Center for Neurological Diseases; Beijing Tiantan Hospital, National Center for Healthcare Quality Management in Neurological Diseases</p> <p>Jiang, YingYu; Beijing Tiantan Hospital, China National Clinical Research Center for Neurological Diseases; Beijing Tiantan Hospital, National Center for Healthcare Quality Management in Neurological Diseases</p> <p>Yang, Xin; Beijing Tiantan Hospital, China National Clinical Research Center for Neurological Diseases; Beijing Tiantan Hospital, National Center for Healthcare Quality Management in Neurological Diseases</p> <p>Wang, Chunjuan; Beijing Tiantan Hospital, China National Clinical Research Center for Neurological Diseases; Beijing Tiantan Hospital, National Center for Healthcare Quality Management in Neurological Diseases</p> <p>Zhao, Xingquan; Beijing Tiantan Hospital, Vascular Neurology, Department of Neurology; Research Unit of Artificial Intelligence in Cerebrovascular Disease, Chinese Academy of Medical Sciences</p> <p>Wang, Yilong; Beijing Tiantan Hospital, China National Clinical Research Center for Neurological Diseases; Beijing Tiantan Hospital, Vascular Neurology, Department of Neurology</p> <p>Liu, Liping; Beijing Tiantan Hospital, Neuro-intensive Care Unit, Department of Neurology</p> <p>Meng, Xia; Beijing Tiantan Hospital, China National Clinical Research Center for Neurological Diseases</p> <p>Li, Hao; Beijing Tiantan Hospital, China National Clinical Research Center for Neurological Diseases</p> <p>Liu, Chelsea; Harvard University T H Chan School of Public Health, Department of Epidemiology</p> <p>Li, Zixiao; Beijing Tiantan Hospital, China National Clinical Research Center for Neurological Diseases; Beijing Tiantan Hospital, National Center for Healthcare Quality Management in Neurological Diseases</p> <p>Wang, Yongjun; Beijing Tiantan Hospital, China National Clinical Research Center for Neurological Diseases; Beijing Tiantan Hospital, National Center for Healthcare Quality Management in Neurological Diseases</p>

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

	Jiang, Yong; Beijing Tiantan Hospital, China National Clinical Research Center for Neurological Diseases
Primary Subject Heading :	Neurology
Secondary Subject Heading:	Public health
Keywords:	Adult neurology < NEUROLOGY, Stroke < NEUROLOGY, VASCULAR MEDICINE

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

Title Page

Thrombolysis, Time-to-Treatment and In-Hospital Outcomes Among Young Adults with Ischemic Stroke in China: Findings from a Nationwide Registry Study in China

Hai-Yan Wang ¹ *; Hong-Qiu Gu ^{2,3} *; Qi Zhou ^{2,3}; Ying-Yu Jiang ^{2,3}; Xin Yang ^{2,3}; Chun-Juan Wang ^{2,3}; Xing-Quan Zhao ^{4,5}; Yi-Long Wang ^{2,4}; Li-Ping Liu ⁶; Xia Meng ²; Hao Li ²; Chelsea Liu ⁷; Zi-Xiao Li ^{2,3}; Yong-Jun Wang ^{2,3}; Yong Jiang ² #;

¹Department of Neurology, Beijing Shijitan Hospital, Capital Medical University, Beijing, China

²China National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University, Beijing, China

³National Center for Healthcare Quality Management in Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University, Beijing, China

⁴Vascular Neurology, Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China

⁵Research Unit of Artificial Intelligence in Cerebrovascular Disease, Chinese Academy of Medical Sciences, Beijing, China

⁶Neuro-intensive Care Unit, Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China

⁷Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA

⁸Beijing Key Laboratory of Translational Medicine for Cerebrovascular Disease, Beijing, China

⁹Center for Stroke, Beijing Institute for Brain Disorders, Beijing, China

* Hai-Yan Wang and Hong-Qiu Gu contributed equally to this paper.

#ADDRESS FOR CORRESPONDENCE

Yong Jiang

China National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University

No.119 West Road, Southern Fourth Ring Road, Fengtai District, Beijing, China, 100070

1
2
3
4 Tel: 86-10-59975806

5
6 Email: jiangyong@ncrcnd.org.cn
7
8
9

10
11 **Key words:** ischemic stroke, young stroke, thrombolysis, door-to-needle time
12
13
14
15

16
17 **Word Count:** 2612
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

ABSTRACT

Background and purpose We aimed to determine whether young adults (< 50 years) with acute ischemic stroke (AIS) are more likely to receive intravenous tissue plasminogen activator (IV tPA) and have shorter time to treatment than older stroke patients.

Methods We analyzed data from the Chinese Stroke Center Alliance (CSCA) registry for AIS patients hospitalized between August 2015 and July 2019. Patients were classified into two groups according to age: young adults (< 50 years of age) and older adults (\geq 50 years of age).

Results Of 793 175 patients with AIS admitted to 1471 hospitals, 9.1% (71 860) were young adults. Compared to older adults, a higher proportion of young adults received IV tPA among patients without contraindications (7.2% vs. 6.1%, adjusted odds ratio [aOR] 1.13, 95% confidence interval [CI] 1.10-1.17) and among patients without contraindications and with onset-to-door time \leq 3.5h (23.6 % vs. 19.3%, aOR 1.20, 95% CI 1.15-1.24). We did not observe differences in onset-to-needle time (median hours 2.7h) or door-to-needle time (DNT) (median minutes 60m) between young and older adults. The proportion of DNT \leq 30 minutes, DNT \leq 45 minutes, and DNT \leq 60 minutes in young and older IV tPA treated patients were 16.9% vs 18.8%, 30.2% vs 32.8% and 50.2% vs 54.2%, respectively. Compared to older adults, young adults treated with IV tPA had lower odds of in-hospital mortality (0.5% vs 1.3%,

1
2
3
4 aOR 0.54, 95% CI 0.35-0.82) and higher odds of independent ambulation at discharge
5
6
7 (61.0% vs 53.6%, aOR 1.15, 95% CI 1.08-1.22), and the associations may be partly
8
9 explained by stroke severity measured by NIHSS score.
10
11

12 **Conclusion** Young adults with AIS were more likely to receive IV tPA than older
13
14 adults, though there was no difference between the two groups in time to treatment.
15
16 Compared with older adults, young adults may had better in-hospital outcomes.
17
18
19
20
21
22
23

24 **Key words:** ischemic stroke, young stroke, thrombolysis, door-to-needle time
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Strengths and limitations of this study

- We used data from a large-scale, nationwide, hospital-based, multicenter quality improvement initiative.
- Multiple regression models adjusted for different levels of covariates were used to check the robustness of the results ;
- Data on intra-arterial therapies, puncture times, door-to-imaging, and follow-up outcomes after discharge were not collected and reported.

ABBREVIATIONS

CSA: Chinese Stroke Association

CSCA: Chinese Stroke Center Alliance

QI: quality improvement

AIS: acute ischemic stroke

BMI: body mass index

mRS: modified Rankin Scale score

aOR: adjusted odds ratios

CI: confidence intervals

IV tPA: intravenous tissue plasminogen activator

IQR: interquartile range

NIHSS: National Institutes of Health Stroke Scale

DNT: door-to-needle time

sICH: symptomatic intracranial hemorrhage

INTRODUCTION

Stroke incidence among adults under 50 years of age has risen in recent years.¹⁻⁵ This creates a significant socioeconomic burden due to high healthcare costs and loss of labor productivity.^{5,6} According to the 2019 Chinese Stroke Statistics, 81.9% of stroke patients had ischemic strokes,⁷ of which young adults constituted 15–18%.⁸ Given this trend, researchers must carefully consider the clinical features and best practices of treatment for strokes in young adults.⁸

Ischemic stroke is a common, preventable, and treatable disease that typically results from thrombotic or thromboembolic blockage of a cerebral artery.⁹ Revascularization therapy plays a major role in the process of saving penumbral tissue from infarction.¹⁰ Tissue plasminogen activator (tPA) is the main intravenous drug approved for the treatment of acute ischemic stroke.¹¹ Treatment of acute occlusive stroke with IV tPA is considered the most regular and important method when given within 4.5 hours of occlusion.^{12,13} While epidemiological studies have been done in other countries regarding IV tPA treatment in young AIS patients, there is limited research on this topic in China.¹³⁻¹⁷

The purpose of this study was to compare the characteristics, IV tPA treatment rates, onset-to-needle time, door-to-needle time (DNT) and in-hospital outcomes of young (<50 years of age) and older (≥ 50 years of age) AIS patients in the Chinese Stroke

1
2
3
4 Center Alliance (CSCA). We hypothesized that young AIS patients would be treated
5
6 more frequently with IV tPA, have shorter treatment time and better in-hospital
7
8 outcomes compared to older adults.
9
10

11 12 13 14 15 **METHODS**

16 17 18 **Data source**

19
20
21
22 CSCA is a national, hospital-based, multicentre, voluntary, multifaceted intervention
23
24 and continuous quality improvement initiative. The data coordinating center of CSCA
25
26 resides at the China National Clinical Research Center for Neurological Diseases
27
28 (NCRCND), Beijing Tiantan Hospital.¹⁸ Trained personnel collected patient
29
30 demographics, medical history, medications, DNT, and in-hospital outcomes, then
31
32 entered this information into a database using a web-based Patient Management Tool
33
34 (Medicine Innovation Research Center, Beijing, China). The tool is characterized by
35
36 predefined logic features, range checks, and user alerts to identify a potentially invalid
37
38 format or value entries and to optimize data quality at the time of entry. Training in
39
40 the use of the tool was provided online and onsite for all users. However, data
41
42 collected by hospitals were not independently audited by external chart review. In
43
44 addition, The China National Clinical Research Center for Neurological Diseases
45
46 serves as the data analysis center and has an agreement to analyze the aggregate
47
48 deidentified data for care quality feedback and research purposes. We abstracted 838
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 229 cases and identified 793 175 patients admitted with ischemic strokes from 2015 to
5
6
7 2019.

10 **Study population**

13 In the first stage, our analyses included patients admitted with AIS within 7 days of
14
15 the onset of symptoms between August 1, 2015 and July 31, 2019 from 1473 hospitals.
16
17 (supplemental material table I)We excluded patients who had in-hospital strokes
18
19 (n=7941, 0.95%), were missing IV tPA information (n=17461, 2.08%), had imprecise
20
21 or undocumented arrival times (n=12), transferred in from an acute care hospital
22
23 (n=1777, 0.212%), or had contraindications to venous thrombolysis within the time
24
25 window (n=17863, 2.13%). This yielded a population of patients with ischemic
26
27 strokes with indications for thrombolysis (n=793175). To analyze DNT and
28
29 in-hospital outcomes of ischemic stroke, we excluded patients treated with IV tPA
30
31 more than 4.5 hours after stroke onset (n=1315, 0.17%) and patients who were not
32
33 treated with IV tPA (n=743719, 93.76%). This yielded a subset of the study
34
35 population that consisted of 48141 AIS patients from 1290 hospitals (Figure 1).
36
37
38
39
40
41
42
43
44
45
46

47 **Outcomes**

48
49
50 The IV tPA treatment rate was assessed among two populations. First, IV tPA rate
51
52 among patients without contraindications to thrombolytic therapy was calculated as
53
54 the number of IV tPA cases divided by the total number of ischemic stroke cases
55
56 without any contraindications to thrombolytic therapy. Then IV tPA rate among
57
58
59
60

1
2
3
4 patients without contraindication to thrombolytic therapy and with onset-to-door time
5
6 ≤ 3.5 h was calculated as the number of IV tPA cases divided by the total number of
7
8 ischemic stroke cases without any contraindications to thrombolytic therapy and
9
10 arrived at a hospital within 3.5 hours after stroke onset. The contraindications were
11
12 defined according to guidelines for the early management of patients with acute
13
14 ischemic stroke from the Heart Association/American Stroke Association and Chinese
15
16 Society of Neurology. DNT was defined as the time between arrival at the emergency
17
18 department (ED) and time of intravenous (IV) thrombolysis, and is an important
19
20 metric in AIS treatment.^{19,20} We analyzed DNT as a binary outcome three times with a
21
22 different cut-off point each time (≤ 30 , ≤ 45 , or ≤ 60 minutes, respectively).
23
24
25
26
27
28
29
30
31
32
33

34 In-hospital outcomes included symptomatic intracranial hemorrhage (sICH),
35
36 in-hospital mortality, and independent ambulation at discharge. sICH was defined as
37
38 intracranial hemorrhage (ICH) within 36 hours of admission, documented by CT or
39
40 MRI, with the treating physician's notes indicating clinical deterioration attributable
41
42 to hemorrhage. Patients who were able to walk < 48 hours after hospital admission
43
44 were considered to have independent ambulation at discharge.
45
46
47
48
49

50 **Statistical analysis**

51
52 Continuous variables with normal distribution were expressed as mean and SD, and
53
54 those with skewed/non-normal distribution as medians and interquartile ranges (IQR).
55
56
57
58
59
60 Categorical variables were summarised as frequencies and percentages. Because of

1
2
3
4 the large sample size, some statistically significant differences may not be clinically
5
6 meaningful. We used absolute standardized differences (ASD) or Hodges–Lehmann
7
8 estimator to compare differences in baseline characteristics between young and older
9
10 adults independent of sample size. An ASD larger than 10% was considered
11
12
13
14
15 meaningful imbalance.²¹

16
17 For outcomes such as IV tPA treatment and in-hospital outcomes, logistic regression
18
19 models were performed to determine adjusted odds ratios (aORs) and 95% confidence
20
21 intervals (CIs). Multivariable models with different level of adjustment were used to
22
23 check the robustness of the results. Covariates in multivariable models including
24
25 gender, insurance status, body mass index (BMI), medical history of prior stroke or
26
27 transient ischemic attack (TIA), coronary artery disease (CAD) or prior myocardial
28
29 infarction (MI), diabetes mellitus, hypertension, smoking status, atrial
30
31 fibrillation/flutter, glycated hemoglobin, diastolic blood pressure, systolic blood
32
33 pressure, medication history (hypoglycemic drugs, antihypertensive drugs, antiplatelet
34
35 drugs, and lipid lowering drugs), and hospital grade.

36
37
38
39
40
41
42
43
44
45
46
47 There were few missing data for most variables, with the exceptions of the in-hospital
48
49 NIHSS score (missing 19.4%), DNT (6.3%), glycated hemoglobin (10.6%) and BMI
50
51 (1.6%). For continuous variables missing less than 15%, the median was used for
52
53 imputation. Since the NIHSS score is a widely used tool for assessing stroke
54
55 severity²² and contributes important information to AIS prognosis,²³ sensitivity
56
57
58
59
60

1
2
3
4 analyses adjusting for the NIHSS score were conducted. In addition, results from
5
6 multiple imputation were also provided.
7
8
9

10
11 All statistical analyses were performed using SAS Version 9.4 (SAS Institute, Cary,
12
13 NC, USA) and the %ggBaseline SAS macro.²⁴ Two-sided p-values of <0.05 were
14
15 considered statistically significant.
16
17
18

19 20 **Patient and public involvement**

21
22 Patients or the public were not involved in the design, or conduct, or reporting, or
23
24 dissemination plans of our research.
25
26
27

28 29 **RESULTS**

30
31 Of 838 229 patients with AIS in the CSCA, 793 175 patients enrolled from 1471
32
33 hospitals were eligible for inclusion in this study. The median age was 67.0 years
34
35 (range: 58.0-75.0) and 62.7% were men. A total of 261 760 (33.0%) patients had
36
37 previous stroke/TIA, 69 810 (8.8%) had coronary artery disease or myocardial
38
39 infarction (CAD/prior MI), 170 638 (21.5%) had diabetes, 510 928 (64.4%) had
40
41 hypertension, 294 708 (37.2%) were smokers, and 40 231 (5.1%) had atrial
42
43 fibrillation/flutter.
44
45
46
47
48
49

50 51 **Clinical characteristics**

52
53 A total of 71 860 (9.1%) patients were young adults (<50 years) and 721 315 (90.9%)
54
55 were older adults (≥50 years). The mean age among young adults was 43.8±5.3 years
56
57
58
59
60

and 68.3±10.0 years among older adults. A larger proportion of the young adults were men (76.3% vs 61.3%) and did not have health insurance coverage (12.9% vs 5.7%), compared to older adults. Young adults had a lower prevalence of cardiovascular risk factors compared to older adults, including history of stroke or TIA (22.5% vs 34.0%), CAD/prior MI (4.0% vs 9.3%), diabetes mellitus (15.3% vs 22.1%), hypertension (53.9% vs 65.5%), and atrial fibrillation (1.2% vs 5.5%). Young adults had a lower rate of medication use than older adults, including hypoglycemic drugs (10.9% vs 17.4%), antihypertensive drugs (33.5% vs 48%), antiplatelet drugs (14.6% vs 21.5%), and lipid lowering drugs (11.4% vs 15.3%). However, diastolic blood pressure in young adults was significantly higher than that of older adults (mean±SD 92.3±16.1 vs mean±SD 86.5±13.5), and young adults had a statistically higher mean BMI than older adults (mean±SD 24.9±4.8 vs mean±SD 23.9±4.2). The proportion of young adults who smoked was also higher than that of older adults (49.9% vs 35.9%) (Table 1).

Table 1. Baseline characteristics of young and old ischemic stroke patients

Baseline characteristics	Total (N=793175 [100%])	Young adults (< 50 years) (N=71860 [9.1%])	Old adults (≥50 years) (N=721315 [90.9%])	ASD (%) / H-L Estimator*
Patient characteristics				
Age, years	66.1±12.0	43.8±5.3	68.3±10.0	306.1
Male, n (%)	496960 (62.7)	54850 (76.3)	442110 (61.3)	32.8
Insurance status, n (%)				
UEBMI	225940 (28.5)	19160 (26.7)	206780 (28.7)	4.5
URBMI	149839 (18.9)	12393 (17.2)	137446 (19.1)	4.9
NRCMS	333979 (42.1)	27587 (38.4)	306392 (42.5)	8.4
Self-pa	50727 (6.4)	9263 (12.9)	41464 (5.7)	25.0

1					
2					
3	Other	32690 (4.1)	3457 (4.8)	29233 (4.1)	3.4
4	Arrive mode, n (%)				
5					
6	Ambulance	89484 (11.3)	7170 (10.0)	82314 (11.4)	4.5
7	Private car	372727 (47.0)	33340 (46.4)	339387 (47.1)	1.4
8	Taxi	68801 (8.7)	6743 (9.4)	62058 (8.6)	2.8
9	Bicycle or tricycle	7237 (0.9)	577 (0.8)	6660 (0.9)	1.1
10	Helicopter	338 (0.0)	27 (0.0)	311 (0.0)	
11	Mobile stroke unit	246 (0.0)	24 (0.0)	222 (0.0)	
12	Other	254342 (32.1)	23979 (33.4)	230363 (31.9)	3.2
13	Medical history, n (%)				
14					
15	Previous stroke/TIA	261760 (33.0)	16197 (22.5)	245563 (34.0)	25.8
16	CAD/prior MI	69810 (8.8)	2906 (4.0)	66904 (9.3)	21.4
17	Diabetes	170638 (21.5)	10985 (15.3)	159653 (22.1)	17.5
18	Peripheral vascular disease	13512 (1.7)	718 (1.0)	12794 (1.8)	6.8
19	Hypertension	510928 (64.4)	38722 (53.9)	472206 (65.5)	23.8
20	Smoking [†]	294708 (37.2)	35848 (49.9)	258860 (35.9)	28.6
21	Atrial fibrillation/flutter	40231 (5.1)	886 (1.2)	39345 (5.5)	24.1
22	Dyslipidemia	60605 (7.6)	5861 (8.2)	54744 (7.6)	2.2
23	Carotid stenosis	10161 (1.3)	509 (0.7)	9652 (1.3)	6.0
24	Medication history, n (%)				
25					
26	Anticoagulants	31326 (3.9)	2394 (3.3)	28932 (4.0)	3.7
27	Hypoglycemic drugs	133244 (16.8)	7802 (10.9)	125442 (17.4)	18.7
28	Antihypertensive drugs	370017 (46.7)	24065 (33.5)	345952 (48.0)	29.8
29	Antiplatelet drugs	165771 (20.9)	10482 (14.6)	155289 (21.5)	18.0
30	Lipid lowering drugs	118827 (15.0)	8171 (11.4)	110656 (15.3)	11.5
31	NIHSS score in hospital [‡]				
32					
33	Mean±SD	4.8±5.2	4.0±4.5	4.9±5.3	18.3
34	Biochemical Indicators				
35					
36	Glycated hemoglobin [§] , %				
37	Median (IQR)	5.8 (5.3–6.5)	5.7 (5.2–6.1)	5.8 (5.3–6.5)	11.4
38	BMI				
39	Mean±SD	24.0±4.3	24.9±4.8	23.9±4.2	22.2
40	Homocysteine [#] , µmol/L				
41	Median (IQR)	13.9 (10.4–19.1)	13.4 (10.0–19.0)	13.9 (10.5–19.1)	2.1
42	Systolic blood pressure ^{* *} , mmHg				
43	Mean±SD	150.0±23.0	147.9±24.4	150.2±22.8	9.7
44	Diastolic blood pressure ^{††} , mmHg				
45	Mean±SD	87.0±13.9	92.3±16.1	86.5±13.5	39.0
46	Hospital characteristics, n (%)				
47					
48	Hospital level				
49					
50					
51					
52					
53					
54					
55					
56					
57					
58					
59					
60					

Secondary hospital	303790 (38.3)	23993 (33.4)	279797 (38.8)	11.3
Tertiary hospital	489385 (61.7)	47867 (66.6)	441518 (61.2)	11.3
Hospital region				
Eastern China	365579 (46.1)	32744 (45.6)	332835 (46.1)	1.0
Central China	262618 (33.1)	24477 (34.1)	238141 (33.0)	2.3
Western China	164978 (20.8)	14639 (20.4)	150339 (20.8)	1.0

Abbreviations: UEBMI, urban employee basic medical insurance; URBMI, urban resident basic medical insurance; NRCMS, new rural cooperative medical scheme; TIA, transient ischemic attack; CAD, coronary artery disease; MI, myocardial infarction; SD: standard deviation; IQR, interquartile range; NIHSS, National Institutes of Health Stroke Scale; ASD, absolute standardized difference.

*HL estimator, Hodges–Lehmann estimator; an absolute standardized difference (%) >10% indicates meaningful imbalance between 2 groups.

†Smoking: having smoking experience or behaviors.

‡Information was missing for N=154052 patients (19.4%).

§Information was missing for N=84393 patients (10.6%); median was used for imputation.

|| Information was missing for N=12698 patients (1.6%); median was used for imputation.

#Information was missing for N= 35781 patients (4.5%).

** Information was missing for N=245 patients (≈0.0%); median was used for imputation.

††Information was missing for N=251 patients (≈0.0%); median was used for imputation.

IV tPA treatment rates

Young adults were treated more frequently with IV tPA than older adults among patients without contraindications to thrombolysis (7.2% vs 6.1%, aOR 1.13, 95% CI 1.10-1.17) and among patients without contraindication and with onset-to-door time ≤ 3.5h (23.6 % vs. 19.3%, aOR 1.20, 95% CI 1.15-1.24). Data from sensitivity analyses showed consistent results.(Table 2)

Table 2. Multivariable analysis of IV tPA treatment by age group

Treatment	Rate of IV-tPA	aOR (95% CI) from model 1	aOR (95% CI) from model 2	aOR (95% CI) from model 3	aOR (95% CI) from model 4
IV tPA among patients without contraindications	49456/793175 (6.2)				
Young adults	5181/71860 (7.2)	1.19 (1.15-1.22)	1.13 (1.10-1.17)	1.20 (1.16-1.24)	1.19(1.15-1.22)
Old adults	44275/721315 (6.1)	1.00	1.00	1.00	1.00
IV tPA among patients	45842/232905(19.7)				

without contraindication
and with onset-to-door
time ≤ 3.5 h

Young adults	4768/20191 (23.6)	1.29 (1.25-1.34)	1.20 (1.15-1.24)	1.24 (1.20-1.29)	1.23(1.19-1.28)
Old adults	41074/212714 (19.3)	1.00	1.00	1.00	1.00

Abbreviations: CI, confidence interval; IV tPA, intravenous recombinant tissue plasminogen activator; OR, odds ratio.

Model 1: Logistic regression model without adjustment.

Model 2: adjusted for gender, insurance, BMI, previous stroke/TIA, previous CAD/prior MI, diabetes, hypertension, have smoking experience or behavior, atrial fibrillation/flutter, glyated, hemoglobin, diastolic blood pressure, hypoglycemic drugs, antihypertensive drugs, antiplatelet drugs, lipid-lowering drugs, and hospital level.

Model 3: adjusted for were in-hospital NIHSS score, gender, insurance, BMI, previous stroke/TIA, previous CAD/prior MI, diabetes, hypertension, have smoking experience or behavior, atrial fibrillation/flutter, glyated hemoglobin, diastolic blood pressure, hypoglycemic drugs, antihypertensive drugs, antiplatelet drugs, lipid-lowering drugs, and hospital level. Patients (N= 154052) with missing values on NIHSS score were not included in this analysis.

model 4: results from multiple imputation.

Treatment time

While young adults were more likely to receive IV tPA, there was no significant difference in onset-to-needle time (median 2.7 hours, IQR 2.0–3.5 for both groups) and DNT (median 60.0 minutes, IQR 42.0-90.0 vs median 60.0 minutes, IQR 36.0-84.0) among young and older adults. DNT was also analyzed as a binary outcome at three levels: DNT ≤ 30 , DNT ≤ 45 , and DNT ≤ 60 minutes. There were no significant differences between the two groups on any DNT level (16.9% vs 18.8%; 30.2% vs 32.8%; 50.2% vs 54.2%) (Table 3).

Table 3. Treatment time in young and old ischemic stroke patients treated with IV tPA

Measures	Total (N=48141 [100%])	Young adults (< 50 years) (N=5044 [10.5%])	Old adults (≥ 50 years) (N=43097 [89.5%])	ASD (%)/H-L Estimator *
Onset-to-needle time [†] ,h				
Median (IQR)	2.7 (2.0–3.5)	2.7 (2.0–3.5)	2.7 (2.0–3.5)	
DNT [‡] ,min				
Median (IQR)	60.0 (36.0–84.0)	60.0 (42.0–90.0)	60.0 (36.0–84.0)	9.7
Treatment time				
DNT ≤ 30 minutes	8938 (18.6)	850 (16.9)	8088 (18.8)	5.0
DNT ≤ 45 minutes	15637 (32.5)	1521 (30.2)	14116 (32.8)	5.6
DNT ≤ 60 minutes	25884 (53.8)	2531 (50.2)	23353 (54.2)	8.0

Abbreviations: CI=confidence interval; IV tPA, intravenous recombinant tissue plasminogen activator; DNT, door-to-needle time; ASD, absolute standardized difference.

*HL estimator, Hodges–Lehmann estimator; an absolute standardized difference (%) $>10\%$ indicates meaningful imbalance between 2 groups.

[†]Onset-to-needle time was missing for 3818 (7.9%) patients, with 431(8.5%) in age <50 and 3387(7.9%) in ≥ 50 groups.

[‡]DNT was missing for 3027(6.3%) patients, with 342 (6.8%) in age <50 and 2685(6.2%) in ≥ 50 groups.

In-hospital outcomes

In-hospital outcomes including sICH, in-hospital mortality, and independent ambulation at discharge were summarized in Table 4. Multiple logistic regression with adjustments of unbalanced covariates (ASD% $>10\%$ in Supplemental Table II) showed that young adults had non-significantly lower rates of sICH (0.5% vs 0.9%, aOR=0.74, 95% CI 0.49-1.11) than older adults. However, young adults had significantly lower rates of in-hospital mortality (0.5% vs 1.3%, aOR=0.54, 95% CI 0.35-0.82) and were more likely to be independently ambulating at discharge (61.0% vs 53.6%, aOR=1.15, 95% CI 1.08-1.22).

1
2
3
4 In sensitivity analyses adjusted for NIHSS scores, young adults had non-significantly
5
6 lower odds of sICH (aOR=0.77, 95%CI 0.5-1.18), in-hospital mortality (aOR=0.70,
7
8 95%CI 0.46-1.09), and a neutral association with independent ambulation at discharge
9
10 (aOR=1.00, 95% CI 0.93-1.08). Sensitivity analysis using different age cut-off point
11
12 (<35 years and \geq 35 years) showed consistent results with primary analysis
13
14 (supplemental material table III). But when we used another age cut of point (<45
15
16 years and \geq 45 years), we had a lower sICH rate (aOR=0.44, 95% CI 0.19-0.99) in
17
18 the young group (supplemental material table IV).
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 4. In-hospital outcomes in young and old ischemic stroke patients treated with IV tPA

Outcome	Rate of outcomes	aOR (95% CI) from model 1	aOR (95% CI) from model 2	aOR (95% CI) from model 3	aOR (95% CI) from model 4
sICH	414/48141 (0.9)				
Young adults	26/5044(0.5)	0.57 (0.38-0.85)	0.74 (0.49-1.11)	0.77 (0.5-1.18)	0.79(0.52-1.20)
Old adults	388/43097(0.9)	1.00	1.00	1.00	1.00
In-hospital mortality	579/48141 (1.2)				
Young adults	24/5044(0.5)	0.37 (0.24-0.55)	0.54 (0.35-0.82)	0.70 (0.46-1.09)	0.65(0.43-1.00)
Old adults	555/43097(1.3)	1.00	1.00	1.00	1.00
Independent ambulation at discharge	26175/48141 (54.4)				
Young adults	3079/5044(61.0)	1.36 (1.28-1.44)	1.15 (1.08-1.22)	1.00 (0.93-1.08)	1.02(0.96-1.10)
Old adults	23096/43097(53.6)	1.00	1.00	1.00	1.00

Abbreviations: CI, confidence interval; IV tPA, intravenous recombinant tissue plasminogen activator; OR, odds ratio.

Model 1: Logistic regression model without adjustment.

Model 2: Adjusted for gender, insurance, BMI, previous stroke/TIA, previous CAD/prior MI, diabetes, hypertension, have smoking experience or behavior, atrial fibrillation/flutter, glycated hemoglobin, diastolic blood pressure, systolic blood pressure, hypoglycemic drugs, antihypertensive drugs, antiplatelet drugs, and lipid-lowering drugs.

Model 3: Adjusted for in-hospital NIHSS score, gender, insurance, BMI, previous stroke/TIA, previous CAD/prior MI, diabetes, hypertension, have smoking experience or behavior, atrial fibrillation/flutter, glycated hemoglobin, diastolic blood pressure, blood pressure, hypoglycemic drugs, antihypertensive drugs, antiplatelet drugs, and lipid-lowering drugs. Patients (N= 2503) with missing values on NIHSS score were not included in this analysis.

model 4: results from multiple imputation.

DISCUSSION

In this hospital-based observational study of 793 175 AIS patients, we found that young adults (<50 years of age) were more likely to be treated with IV tPA than older adults (7.2% vs 6.1%), which was consistent with our hypothesis. Our study demonstrated that young stroke patients had fewer comorbidities (previous stroke/TIA, previous CAD/prior MI, diabetes, hypertension, and atrial fibrillation/flutter) at baseline, which may compel providers to feel more secure in administering IV tPA to this group of patients. Even though we did not observe a difference in DNT between age groups, we found that young adults had more favorable in-hospital outcomes than older adults, including lower odds of sICH, in-hospital mortality and higher odds of independent ambulation at discharge. However, after adjusting for NIHSS scores, the differences were not significant. Therefore, the benefit among young adults may be explained by stroke severity measured by NIHSS score.

We chose 50 as the cut-off age because several important international studies on thrombolytic therapy in young people also set the cut-off age at 50.^{15,16} Using the same cut-off age value would benefit the comparison with other studies and also have advantages for potential systematic review and meta-analysis.

IV tPA thrombolytic therapy is considered to be the standard therapy in patients with acute ischemic stroke. However, its use has been studied primarily in adults over age

1
2
3
4 50.¹⁶ Given increasing evidence in the literature that thrombolytic therapy rarely
5
6 causes hemorrhages in patients with stroke-mimicking conditions, providers may also
7
8 feel more comfortable administering IV tPA to young adults when it is uncertain
9
10 whether a stroke or a stroke mimic had occurred.²⁵ Our research also supports this
11
12 conclusion. Young adults had similar time to treatment and were more likely to be
13
14 treated than older adults, which may reflect increased awareness among patients and
15
16 clinicians that stroke is a potentially fatal disease affecting people of all ages.
17
18
19
20
21
22
23
24
25

26 The relationship between time to treatment and mortality was first recognized in
27
28 clinical studies.^{26,27} The importance of this metric was reemphasized in the 2004
29
30 American College of Cardiology/American Heart Association practice guidelines,
31
32 which stated that DNT targets “should not be perceived as an average performance
33
34 standard but as a goal that an early treatment system in every hospital should seek for
35
36 every appropriate patient”.²⁸ Consistent with a prior analysis of SITS-ISTR showing
37
38 no difference in median door-to-needle times between patients 18 to 50 and >50 years
39
40 of age, there was also not an obvious differentiation in treatment among young or
41
42 older adults in our study.¹⁵ However, a prior study by Dodds and colleagues found
43
44 that young adults (18-40 years) with AIS were more likely to experience a delay in
45
46 evaluation and treatment.¹³ Our definition of young adults (age <50 years) differs
47
48 from theirs (age 18–40 years) and is more applicable in China, which may also
49
50 explain why we did not find differences in treatment times between the two groups.²⁹
51
52
53
54
55
56
57
58
59
60

1
2
3
4 Another explanation for the lack of differences in treatment times between the two
5
6 groups may be that DNT mainly depends on hospital level and treatment process
7
8 rather than age.
9
10

11
12
13
14
15 In our study, we observed a higher rate of sICH and in-hospital mortality among older
16
17 adults treated with IV tPA, though the difference was not significant adjusted for
18
19 NIHSS scores. We cannot entirely separate young age from lower NIHSS score, as
20
21 young patients are highly correlated with lower NIHSS scores in clinical practise
22
23 (4.0±4.5 vs. 4.9±5.3, the Rank Biserial correlation coefficient in this study is 0.10,
24
25 p<0.001). Therefore, the associations may be partly explained by stroke severity
26
27 measured by NIHSS score. Although we do not find significant differences between
28
29 these two groups, we do see a trend towards better outcomes in young people. One
30
31 possible explanation is that younger stroke patients have fewer comorbidities in their
32
33 medical history, such as previous stroke or TIA, CAD/MI, diabetes mellitus,
34
35 hypertension, and atrial fibrillation, as well as milder strokes, all of which are
36
37 associated with better outcomes.³⁰ Other factors favoring recovery in young stroke
38
39 patients include greater brain plasticity and more robust family and social support.³¹
40
41
42
43
44
45
46
47
48
49
50

51
52
53 There are several limitations in our study. Since hospital participation in the CSCA is
54
55 voluntary, participating hospitals are more likely to be larger, tertiary centers with a
56
57 myriad of resources that smaller hospitals do not have access to. We recognize that
58
59
60

1
2
3
4 findings from CSCA may not be generalizable to AIS patients admitted to hospitals
5
6 outside of the CSCA. Second, we did not report data on intra-arterial (IA) therapies
7
8 and puncture times because only a very small number of patients in our study received
9
10 thrombectomy. We also did not have door-to-imaging data to support the study and
11
12 there was a relatively high proportion of missing DNT values (6.3% overall, 6.8% in
13
14 young and 6.2% in older patients). However, we did not observe a significant
15
16 difference in DNTs between young and older AIS patients. Lastly, although we
17
18 provided some possible explanation for the differences between young and old adults
19
20 group, further researches are needed to explore the detailed mechanism.
21
22
23
24
25
26
27
28
29
30

31 **CONCLUSION**

32
33
34
35 In summary, young adults with AIS are more likely to receive IV tPA than older
36
37 adults, but there is no difference between the two groups in time to treatment. Young
38
39 adults may have better in-hospital outcomes compared with older adults, suggesting
40
41 favorable effects of treatment with IV tPA.
42
43
44
45
46
47
48

49 **ACKNOWLEDGEMENTS**

50
51
52 We thank the staff and participants of the CSCA (Chinese Stroke Center Alliance)
53
54 studies for their contribution.
55
56
57
58
59
60

CONTRIBUTORS

Conceived and led the project: XZ, YW, ZL, YW and YJ. Conception and design:

HW, HG, YW and YJ. Data collection and analysis: HW, XY, CW, HG and QZ.

Interpret the data: LL, XM and HL. Drafting the article and revising the content: HW,

HG, CL, JY and ZL. All authors approved the final version of the manuscript.

FUNDING

The Chinese Stroke Center Alliance program was supported by grants from the

Ministry of Science and Technology and the Ministry of Health of the People's

Republic of China (National Key R&D Program of China, Code: 2016YFC0901001,

2017YFC1310901, 2016YFC0901002, 2017YFC1307905, 2015BAI12B00), Beijing

Talents Project (2018A13, 2018000021223ZK03), CAMS Innovation Fund for

Medical Sciences (2019-I2M-5-029), Beijing Municipal Committee of Science and

Technology (Z201100005620010), Beijing Natural Science Foundation (Z200016).

COMPETING INTERESTS

None declared.

PATIENT CONSENT FOR PUBLICATION

Not required.

ETHICS APPROVAL

This study received approval from the Institutional Review Board/Ethics Committee of Beijing Tiantan Hospital, Capital Medical University with approval number KY 2018-061-02. Participating hospitals received research approval to collect data in CSCA without requiring individual patient informed consent under the common rule or a waiver of authorisation and exemption from their Institutional Review Board.

DATA AVAILABILITY STATEMENT

Data are available upon reasonable request. The data that support the findings of this study are available from the corresponding author upon reasonable request and after clearance by the local ethics committee.

REFERENCES

1. Béjot Y, Bailly H, Durier J, et al. Epidemiology of stroke in Europe and trends for the 21st century. *Presse Med* 2016;45:e391-8. doi: 10.1016/j.lpm.2016.10.003 [published Online First: 2016/11/07]
2. Hathidara MY, Saini V, Malik AM. Stroke in the young: A global update. *Current neurology and neuroscience reports* 2019;19:91. doi: 10.1007/s11910-019-1004-1 [published Online First: 2019/11/27]
3. Rutten-Jacobs LC, Maaijwee NA, Arntz RM, et al. Risk factors and prognosis of

1
2
3
4 young stroke. The FUTURE study: a prospective cohort study. Study rationale and
5
6 protocol. *BMC Neurol* 2011;11:109. doi: 10.1186/1471-2377-11-109 [published
7
8 Online First: 2011/09/22]
9

10
11
12 4. George MG. Risk Factors for Ischemic Stroke in Younger Adults: A Focused
13
14 Update. *Stroke* 2020;51:729-35. doi: 10.1161/strokeaha.119.024156 [published
15
16 Online First: 2020/02/23]
17

18
19
20 5. Maaijwee NA, Rutten-Jacobs LC, Schaapsmeeders P, et al. Ischaemic stroke in
21
22 young adults: risk factors and long-term consequences. *Nat Rev Neurol*
23
24 2014;10:315-25. doi: 10.1038/nrneurol.2014.72 [published Online First: 2014/04/30]
25
26

27
28 6. Feigin VL, Roth GA, Naghavi M, et al. Global burden of stroke and risk factors in
29
30 188 countries, during 1990–2013: a systematic analysis for the Global Burden of
31
32 Disease Study 2013. *The Lancet Neurology* 2016;15:913-24. doi:
33
34 10.1016/s1474-4422(16)30073-4
35
36

37
38
39 7. Wang Y-J, Li Z-X, Gu H-Q, et al. China Stroke Statistics 2019: A Report From the
40
41 National Center for Healthcare Quality Management in Neurological Diseases, China
42
43 National Clinical Research Center for Neurological Diseases, the Chinese Stroke
44
45 Association, National Center for Chronic and Non-communicable Disease Control
46
47 and Prevention, Chinese Center for Disease Control and Prevention and Institute for
48
49 Global Neuroscience and Stroke Collaborations. *Stroke and Vascular Neurology*
50
51 2020;5:211-39. doi: 10.1136/svn-2020-000457
52
53
54
55

56
57
58 8. Singhal AB, Biller J, Elkind MS, et al. Recognition and management of stroke in
59
60

- 1
2
3
4 young adults and adolescents. *Neurology* 2013;81:1089-97. doi:
5
6 10.1212/WNL.0b013e3182a4a451 [published Online First: 2013/08/16]
7
8
9 9. Peña-Martínez C, Durán-Laforet V, García-Culebras A, et al. Pharmacological
10
11 Modulation of Neutrophil Extracellular Traps Reverses Thrombotic Stroke tPA
12
13 (Tissue-Type Plasminogen Activator) Resistance. *Stroke* 2019;50:3228-37. doi:
14
15 10.1161/strokeaha.119.026848 [published Online First: 2019/09/19]
16
17
18 10. Martínez-Sánchez P, Díez-Tejedor E, Fuentes B, et al. Systemic Reperfusion
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
10. Martínez-Sánchez P, Díez-Tejedor E, Fuentes B, et al. Systemic Reperfusion Therapy in Acute Ischemic Stroke. *Cerebrovascular Diseases* 2007;24:143-52. doi: 10.1159/000107390
11. Powers WJ, Rabinstein AA, Ackerson T, et al. Guidelines for the Early Management of Patients With Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. *Stroke* 2019;50:e344-e418. doi:10.1161/STR.0000000000000211
12. Berge E, Whiteley W, Audebert H, et al. European Stroke Organisation (ESO) guidelines on intravenous thrombolysis for acute ischaemic stroke. *Eur Stroke J* 2021;6:I-LXII. doi: 10.1177/2396987321989865
13. Dodds JA, Xian Y, Sheng S, et al. Thrombolysis in young adults with stroke: Findings from Get With The Guidelines-Stroke. *Neurology* 2019;92:e2784-92. doi: 10.1212/wnl.00000000000007653 [published Online First: 2019/05/17]
14. Papavasileiou V, Goldstein LB. Thrombolysis in young adults with acute ischemic

1
2
3
4 stroke. *Neurology* 2019;92:1129-30. doi: 10.1212/wnl.00000000000007651
5

6
7 15. Toni D, Ahmed N, Anzini A, et al. Intravenous thrombolysis in young stroke
8
9 patients: results from the SITS-ISTR. *Neurology* 2012;78:880-7. doi:
10
11 10.1212/WNL.0b013e31824d966b [published Online First: 2012/03/10]
12
13

14
15 16. Poppe AY, Buchan AM, Hill MD. Intravenous thrombolysis for acute ischaemic
16
17 stroke in young adult patients. *Can J Neurol Sci* 2009;36:161-7. doi:
18
19 10.1017/s031716710012027x [published Online First: 2009/04/22]
20
21
22

23
24 17. Shi J, Cao Y, You S, et al. Young Stroke Patients Treated with Intravenous
25
26 Thrombolysis have a More Favorable Outcome and Mortality Compared with Older
27
28 Patients. *Curr Neurovasc Res* 2017;14:141-48. doi:
29
30 10.2174/1567202614666170328095431 [published Online First: 2017/03/31]
31
32
33

34
35 18. Wang Y, Li Z, Wang Y, et al. Chinese Stroke Center Alliance: a national effort to
36
37 improve healthcare quality for acute stroke and transient ischaemic attack: rationale,
38
39 design and preliminary findings. *Stroke Vasc Neurol* 2018;3:256-62. doi:
40
41 10.1136/svn-2018-000154 [published Online First: 2019/01/15]
42
43
44

45
46 19. Hsieh CY, Chen WF, Chen CH, et al. Efforts to reduce the door-to-needle time of
47
48 thrombolysis in acute ischemic stroke: video-assisted therapeutic risk communication.
49
50 *J Formos Med Assoc* 2014;113:929-33. doi: 10.1016/j.jfma.2013.11.012 [published
51
52 Online First: 2014/01/15]
53
54

55
56 20. van Tuijn CF, Luitse JS, van der Valk M, et al. Reduction of the door-to-needle
57
58 time for administration of antibiotics in patients with a severe infection: a tailored
59
60

1
2
3
4 intervention project. *Neth J Med* 2010;68:123-7.
5

6
7 21. Austin PC. Balance diagnostics for comparing the distribution of baseline
8
9 covariates between treatment groups in propensity-score matched samples. *Stat Med*
10
11 2009;28:3083-107. doi: 10.1002/sim.3697 [published Online First: 2009/09/17]
12
13

14
15 22. Habib M, Karim ASMR, Hossain MM, et al. Assessment of Initial Stroke Severity
16
17 by National Institute Health Stroke Scale (NIHSS) Score at Admission. *Journal of*
18
19 *Dhaka Medical College* 2018;26:90-93. doi: 10.3329/jdmc.v26i2.38765
20
21

22
23 23. Chen X, Zhan X, Chen M, et al. The prognostic value of combined NT-pro-BNP
24
25 levels and NIHSS scores in patients with acute ischemic stroke. *Intern Med*
26
27 2012;51:2887-92. doi: 10.2169/internalmedicine.51.8027 [published Online First:
28
29 2012/10/16]
30
31

32
33 24. Gu HQ, Li DJ, Liu C, et al. %ggBaseline: a SAS macro for analyzing and
34
35 reporting baseline characteristics automatically in medical research. *Ann Transl Med*
36
37 2018;6:326. doi: 10.21037/atm.2018.08.13 [published Online First: 2018/10/27]
38
39

40
41 25. Zinkstok SM, Engelter ST, Gensicke H, et al. Safety of thrombolysis in stroke
42
43 mimics: results from a multicenter cohort study. *Stroke* 2013;44:1080-4. doi:
44
45 10.1161/STROKEAHA.111.000126
46
47

48
49 26. Cannon CP, Gibson CM, Lambrew CT, et al. Relationship of
50
51 symptom-onset-to-balloon time and door-to-balloon time with mortality in patients
52
53 undergoing angioplasty for acute myocardial infarction. *Jama* 2000;283:2941-7. doi:
54
55 10.1001/jama.283.22.2941 [published Online First: 2000/06/24]
56
57
58
59
60

- 1
2
3
4 27. Schull MJ, Vermeulen M, Donovan L, et al. Can the wrong statistic be bad for
5
6 health? Improving the reporting of door-to-needle time performance in acute
7
8 myocardial infarction. *Am Heart J* 2005;150:583-7. doi: 10.1016/j.ahj.2005.03.061
9
10 [published Online First: 2005/09/20]
11
12
13
14 28. Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the
15
16 management of patients with ST-elevation myocardial infarction--executive summary:
17
18 a report of the American College of Cardiology/American Heart Association Task
19
20 Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for
21
22 the Management of Patients With Acute Myocardial Infarction). *Circulation*
23
24 2004;110:588-636. doi: 10.1161/01.Cir.0000134791.68010.Fa [published Online First:
25
26 2004/08/04]
27
28
29
30
31
32
33 29. Xiaobing Z SH, Li'an H. Clinical investigation of stroke in young and
34
35 middle-aged adults. *Cerebrovascular Diseases Foreign Medical Sciences*
36
37 2004;012:354-7.
38
39
40
41 30. Arnold M, Halpern M, Meier N, et al. Age-dependent differences in demographics,
42
43 risk factors, co-morbidity, etiology, management, and clinical outcome of acute
44
45 ischemic stroke. *Journal of Neurology* 2008;255:1503-07. doi:
46
47 10.1007/s00415-008-0949-9
48
49
50
51
52 31. Popa-Wagner A, Carmichael ST, Kokaia Z, et al. The response of the aged brain
53
54 to stroke: too much, too soon? *Curr Neurovasc Res* 2007;4:216-27. doi:
55
56 10.2174/156720207781387213 [published Online First: 2007/08/19]
57
58
59
60

1
2
3
4
5 **Figure legend**
6

7 Figure 1. Study flowchart for patients identification.

8 Abbreviations: IV tPA, intravenous tissue plasminogen activator.
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Source population

Admission (N=838229)
Hospital (N=1473)
August 1, 2015 to July 31, 2019

Excluded (n=45054)

- In-hospital stroke (7941)
- Missing IV tPA information (17461)
- Missing arrival time (12)
- Transferred in from acute care hospital (1777)
- Contraindications to venous thrombolysis within a time window (17863)

Analysis of outcomes in all ischemic stroke

Admission (N=793175)
Hospital (N=1471)

Excluding (n=745034)

- Treated with tPA but >4.5h (1315) Not
- treated with tPA (743719)

Analysis of treatment times, and outcomes in patients treated with tPA within 4.5 hours

Admission (N=48141)
Hospital (N=1290)

Supplemental Material

1

2 Table I . Distribution of hospitals in our study

3

Hospital region	Province or Municipality	Number of hospitals (N=676)	Hospital region	Province or Municipality	Number of hospitals (N=401)	Hospital region	Province or Municipality	Number of hospitals (N=394)
Eastern China	Beijing	16	Central China	Jilin	32	Western China	Inner Mongolia	23
	Tianjin	13		Heilongjiang	41		Guangxi	49
	Hebei	143		Shanxi	44		Chongqing	16
	Liaoning	53		Anhui	29		Sichuan	125
	Shanghai	16		Jiangxi	25		Guizhou	23
	Jiangsu	93		Henan	157		Yunnan	52
	Zhejiang	86		Hubei	39		Tibet	1
	Fujian	52		Hunan	34		Shaanxi	41
	Shandong	81					Gansu	33
	Guangdong	113					Qinghai	9
	Hainan	10					Ningxia	5
							Xinjiang	17

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

Table 2. Baseline characteristics of young and old ischemic stroke patients with IV tPA treatment

Baseline characteristics	Total (N=48141 [100%])	Young adults (< 50 years) (N=5044 [10.5%])	Old adults (≥50 years) (N=43097 [89.5%])	ASD*
Patient characteristics				
Age, years				
Mean±SD	65.2±12.1	43.4±5.6	67.8±9.8	305.7
Male, n (%)	31456 (65.3)	3961 (78.5)	27495 (63.8)	32.9
Insurance status, n (%)				
UEBMI	15948 (33.1)	1609 (31.9)	14339 (33.3)	3.0
URBMI	9813 (20.4)	913 (18.1)	8900 (20.7)	6.6
NRCMS	16442 (34.2)	1495 (29.6)	14947 (34.7)	10.9
Self-pa	4083 (8.5)	813 (16.1)	3270 (7.6)	26.5
Other	1855 (3.9)	214 (4.2)	1641 (3.8)	2.0
Arrive mode, n (%)				
Ambulance	14364 (29.8)	1352 (26.8)	13012 (30.2)	7.5
Private car	21213 (44.1)	2240 (44.4)	18973 (44.0)	0.8
Taxi	2539 (5.3)	357 (7.1)	2182 (5.1)	8.4
Bicycle or tricycle	118 (0.2)	7 (0.1)	111 (0.3)	4.5
Helicopter	14 (0.0)	1 (0.0)	13 (0.0)	
Mobile stroke unit	31 (0.1)	4 (0.1)	27 (0.1)	0.0
Other	9862 (20.5)	1083 (21.5)	8779 (20.4)	2.7
Medical history, n (%)				
Previous stroke/TIA	12339 (25.6)	830 (16.5)	11509 (26.7)	25.0
CAD/prior MI	4737 (9.8)	240 (4.8)	4497 (10.4)	21.3
Diabetes	8477 (17.6)	516 (10.2)	7961 (18.5)	23.8
Peripheral vascular disease	628 (1.3)	31 (0.6)	597 (1.4)	8.0
Hypertension	28815 (59.9)	2283 (45.3)	26532 (61.6)	33.1
Smoking [†]	18835 (39.1)	2567 (50.9)	16268 (37.7)	26.8
Atrial fibrillation/flutter	5692 (11.8)	138 (2.7)	5554 (12.9)	38.7
Dyslipidemia	3195 (6.6)	351 (7.0)	2844 (6.6)	1.6
Carotid stenosis	454 (0.9)	22 (0.4)	432 (1.0)	7.2
Medication history, n (%)				
Anticoagulants	1779 (3.7)	150 (3.0)	1629 (3.8)	4.4
Hypoglycemic drugs	6404 (13.3)	330 (6.5)	6074 (14.1)	25.2
Antihypertensive drugs	20099 (41.8)	1302 (25.8)	18797 (43.6)	38.1
Antiplatelet drugs	7882 (16.4)	467 (9.3)	7415 (17.2)	23.5
Lipid lowering drugs	5614 (11.7)	382 (7.6)	5232 (12.1)	15.1
NIHSS score in hospital [‡]				
Mean±SD	7.9±6.5	6.4±5.3	8.0±6.6	26.7

(Continued)

56
57
58
59
60

Table II. Baseline characteristics of young and old ischemic stroke patients with IV tPA treatment

Baseline characteristics	Total (N=48141 [100%])	Young adults (< 50 years) (N=5044 [10.5%])	Old adults (≥50 years) (N=43097 [89.5%])	ASD*
Biochemical Indicators				
Glycated hemoglobin ^s , %				
Median (IQR)	5.8 (5.3–6.4)	5.6 (5.1–6.0)	5.8 (5.3–6.5)	
BMI ^l				
Mean±SD	23.6±4.2	24.9±5.5	23.4±4.0	31.2
Homocysteine [#] , μmol/L				
Median (IQR)	13.3 (10.0–18.5)	12.7 (9.6–18.9)	13.3 (10.1–18.5)	
Systolic blood pressure* *, mmHg				
Mean±SD	152.5±23.8	148.3±24.6	153.0±23.7	19.5
Diastolic blood pressure ⁺⁺ , mmHg				
Mean±SD	87.6±14.5	92.1±16.1	87.1±14.2	32.9
Hospital characteristics, n (%)				
Hospital level				
Secondary hospital	16479 (34.2)	1735 (34.4)	14744 (34.2)	0.4
Tertiary hospital	31662 (65.8)	3309 (65.6)	28353 (65.8)	0.4
Hospital region				
Eastern China	26410 (54.9)	2792 (55.4)	23618 (54.8)	1.2
Central China	15024 (31.2)	1630 (32.3)	13394 (31.1)	2.6
Western China	6707 (13.9)	622 (12.3)	6085 (14.1)	5.3

Abbreviations: IV tPA, intravenous recombinant tissue plasminogen activator; UEBMI, urban employee basic medical insurance; URBMI, urban resident basic medical insurance; NRCMS, new rural cooperative medical scheme; TIA, transient ischemic attack; CAD, coronary artery disease; MI, myocardial infarction; SD: standard deviation; IQR, interquartile range; NIHSS, National Institutes of Health Stroke Scale; ASD, absolute standardized difference.

*: An absolute standardized difference% >10% indicates meaningful imbalance between 2 groups.

[†]: Smoking: having smoking experience or behaviors.

[‡]: Information was missing for N = 2503 patients (5.2%).

[§]: Information was missing for N = 4749 patients (9.9%), using the median for imputation.

^{||}: Information was missing for N = 743 patients (1.5%), using the median for imputation.

[#]: Information was missing for N = 2682 patients (5.6%).

* *: Information was missing for N = 28 patients (0.1 %), using the median for imputation.

⁺⁺: Information was missing for N = 28 patients (0.1%), using the median for imputation.

Table III. In-hospital outcomes in young (< 35 years) and old (≥ 35 years) ischemic stroke patients treated with IV tPA

Outcome	Total (N=48141 [100%])	young adults (< 35 years) (N=456 [0.9%])	old adults (≥ 35 years) (N=47685[99.1%])(REF)	Model	OR (95% CI)	P value
sICH	414 (0.9)	4 (0.9)	410 (0.9)	1	1.02 (0.38-2.74)	0.9678
				2	1.45 (0.54-3.94)	0.4612
				3	1.52 (0.56-4.13)	0.4136
In-hospital mortality	579 (1.2)	1 (0.2)	578 (1.2)	1	0.18 (0.03-1.28)	0.0861
				2	0.28 (0.04-2.01)	0.2066
				3	0.27 (0.04-1.97)	0.1953
Independent ambulation at discharge	26175 (54.4)	279 (61.2)	25896 (54.3)	1	1.33 (1.10-1.60)	0.0034
				2	1.09 (0.90-1.32)	0.384
				3	1.15 (0.92-1.42)	0.2173

Abbreviations: CI, confidence interval; IV tPA, intravenous recombinant tissue plasminogen activator ; OR, odds ratio.

Model 1: Logistic regression model without adjustment.

Model 2: Adjusted for gender, insurance, BMI, previous stroke/TIA, previous CAD/prior MI, diabetes, hypertension, have smoking experience or behavior, atrial fibrillation/flutter, glyated hemoglobin, diastolic blood pressure, systolic blood pressure, hypoglycemic drugs, antihypertensive drugs, antiplatelet drugs, and lipid-lowering drugs.

Model 3: Adjusted for in-hospital NIHSS score, gender, insurance, BMI, previous stroke/TIA, previous CAD/prior MI, diabetes, hypertension, have smoking experience or behavior, atrial fibrillation/flutter, glyated hemoglobin, diastolic blood pressure, blood pressure, hypoglycemic drugs, antihypertensive drugs, antiplatelet drugs, and lipid-lowering drugs. Patients (N= 2503) with missing values on NIHSS score were not included in this analysis.

Table IV. In-hospital outcomes in young (< 45 years) and old (≥45 years) ischemic stroke patients treated with IV tPA

Outcome	Total (N=48141 [100%])	young adults (< 45 years) (N=2244 [4.7%])	old adults (≥45 years) (N=45897[95.3%])(REF)	Model	OR (95% CI)	P value
sICH	414 (0.9)	8 (0.4)	406 (0.9)	1	0.40 (0.20-0.81)	0.0106
				2	0.54 (0.26-1.10)	0.0877
				3	0.44 (0.19-0.99)	0.048
In-hospital mortality	579 (1.2)	8 (0.4)	571 (1.2)	1	0.28 (0.14-0.57)	0.0004
				2	0.43 (0.21-0.87)	0.0197
				3	0.52 (0.26-1.07)	0.077
Independent ambulation at discharge	26175 (54.4)	1356 (60.4)	24819 (54.1)	1	1.30 (1.19-1.41)	<0.0001
				2	1.08 (0.98-1.18)	0.1082
				3	0.97 (0.88-1.08)	0.6096

Abbreviations: CI, confidence interval; IV tPA, intravenous recombinant tissue plasminogen activator ; OR, odds ratio.

Model 1: Logistic regression model without adjustment.

Model 2: Adjusted for gender, insurance, BMI, previous stroke/TIA, previous CAD/prior MI, diabetes, hypertension, have smoking experience or behavior, atrial fibrillation/flutter, glycated hemoglobin, diastolic blood pressure, systolic blood pressure, hypoglycemic drugs, antihypertensive drugs, antiplatelet drugs, and lipid-lowering drugs.

Model 3: Adjusted for in-hospital NIHSS score, gender, insurance, BMI, previous stroke/TIA, previous CAD/prior MI, diabetes, hypertension, have smoking experience or behavior, atrial fibrillation/flutter, glycated hemoglobin, diastolic blood pressure, blood pressure, hypoglycemic drugs, antihypertensive drugs, antiplatelet drugs, and lipid-lowering drugs. Patients (N= 2503) with missing values on NIHSS score were not included in this analysis.

STROBE Statement—checklist of items that should be included in reports of observational studies

Section/item	Item No	Recommendation	Page No.	Relevant text from manuscript
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	Page1,3,4	Title,Abstract/Para1-2
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	Page3-4	Abstract/Para2-4
Introduction				
Background/ rationale	2	Explain the scientific background and rationale for the investigation being reported	Page7	Introduction/Para1-2
Objectives	3	State specific objectives, including any prespecified hypotheses	Page7-8	Introduction/Para3
Methods				
Study design	4	Present key elements of study design early in the paper	Page8-9	Methods/Para1
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	Page9-10	Methods/Para2-4
Participants	6	(a) Cohort study —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up Case-control study —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls Cross-sectional study —Give the eligibility criteria, and the sources and methods of selection of participants	Page8-10	Methods/Para1-4
		(b) Cohort study —For matched studies, give matching criteria and number of exposed and unexposed Case-control study —For matched studies, give matching criteria and the number of controls per case		
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	Page9-10	Methods/Para3-4
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	Page8-11	Methods/Para1-6
Bias	9	Describe any efforts to address potential sources of bias	Page10-12	Methods/Para5-7
Study size	10	Explain how the study size was arrived at	Page8-9	Methods/Para1-2
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	Page10-11	Methods/Para5

Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	Page10-12	Methods/Para5-8
		(b) Describe any methods used to examine subgroups and interactions	Page10-11	Methods/Para5
		(c) Explain how missing data were addressed	Page11-12	Methods/Para7
		(d) Cohort study —If applicable, explain how loss to follow-up was addressed Case-control study —If applicable, explain how matching of cases and controls was addressed Cross-sectional study —If applicable, describe analytical methods taking account of sampling strategy	Page11-12	Methods/Para7
		(e) Describe any sensitivity analyses	Page11-12	Methods/Para7
Results				
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	Page12	Results/Para1
		(b) Give reasons for non-participation at each stage		Figure1
		(c) Consider use of a flow diagram		Figure1
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	Page12-15	Results/Para1-2
		(b) Indicate number of participants with missing data for each variable of interest	Page15	Results/table1
		(c) Cohort study —Summarise follow-up time (eg, average and total amount)		
Outcome data	15*	Cohort study —Report numbers of outcome events or summary measures over time	Page15-19	Results/Para3-6
		Case-control study —Report numbers in each exposure category, or summary measures of exposure		
		Cross-sectional study —Report numbers of outcome events or summary measures		
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	Page15-19	Results/Para3-6
		(b) Report category boundaries when continuous variables were categorized	Page15-17	Results/Para3-6
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period		
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	Page15-19	Results/Para3-6
Discussion				
Key results	18	Summarise key results with reference to study objectives	Page20-22	Discussion/Para1-5
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	Page22-23	Discussion/Para6

1	2	3	4	5	6	7	8	9
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	Page19-22	Discussion/Para2-5				
Generalisability	21	Discuss the generalisability (external validity) of the study results	Page23	Discussion/Para6				
Other information								
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	Page24	Funding				

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

BMJ Open

Thrombolysis, Time-to-Treatment and In-Hospital Outcomes Among Young Adults with Ischemic Stroke in China: Findings from a Nationwide Registry Study in China

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-055055.R2
Article Type:	Original research
Date Submitted by the Author:	15-Apr-2022
Complete List of Authors:	<p>Wang, HaiYan; Beijing Shijitan Hospital, Capital Medical University, Department of Neurology and Psychiatry</p> <p>Gu, Hongqiu; Beijing Tiantan Hospital, Capital Medical University, China National Clinical Research Center for Neurological Diseases; Beijing Tiantan Hospital, Capital Medical University, National Center for Healthcare Quality Management in Neurological Diseases</p> <p>Zhou, Qi; Beijing Tiantan Hospital, Capital Medical University, China National Clinical Research Center for Neurological Diseases; Beijing Tiantan Hospital, Capital Medical University, National Center for Healthcare Quality Management in Neurological Diseases</p> <p>Jiang, YingYu; Beijing Tiantan Hospital, Capital Medical University, China National Clinical Research Center for Neurological Diseases; Beijing Tiantan Hospital, Capital Medical University, National Center for Healthcare Quality Management in Neurological Diseases</p> <p>Yang, Xin; Beijing Tiantan Hospital, Capital Medical University, China National Clinical Research Center for Neurological Diseases; Beijing Tiantan Hospital, Capital Medical University, National Center for Healthcare Quality Management in Neurological Diseases</p> <p>Wang, Chunjuan; Beijing Tiantan Hospital, Capital Medical University, China National Clinical Research Center for Neurological Diseases; Beijing Tiantan Hospital, Capital Medical University, National Center for Healthcare Quality Management in Neurological Diseases</p> <p>Zhao, Xingquan; Beijing Tiantan Hospital, Capital Medical University, Vascular Neurology, Department of Neurology; Research Unit of Artificial Intelligence in Cerebrovascular Disease, Chinese Academy of Medical Sciences</p> <p>Wang, Yilong; Beijing Tiantan Hospital, Capital Medical University, China National Clinical Research Center for Neurological Diseases; Beijing Tiantan Hospital, Capital Medical University, Vascular Neurology, Department of Neurology</p> <p>Liu, Liping; Beijing Tiantan Hospital, Capital Medical University, Neuro-intensive Care Unit, Department of Neurology</p> <p>Meng, Xia; Beijing Tiantan Hospital, Capital Medical University, China National Clinical Research Center for Neurological Diseases</p> <p>Li, Hao; Beijing Tiantan Hospital, Capital Medical University, China National Clinical Research Center for Neurological Diseases</p> <p>Liu, Chelsea; Harvard University T H Chan School of Public Health, Department of Epidemiology</p> <p>Li, Zixiao; Beijing Tiantan Hospital, Capital Medical University, China</p>

	National Clinical Research Center for Neurological Diseases; Beijing Tiantan Hospital, Capital Medical University, National Center for Healthcare Quality Management in Neurological Diseases Wang, Yongjun; Beijing Tiantan Hospital, Capital Medical University, China National Clinical Research Center for Neurological Diseases; Beijing Tiantan Hospital, Capital Medical University, National Center for Healthcare Quality Management in Neurological Diseases Jiang, Yong; Beijing Tiantan Hospital, China National Clinical Research Center for Neurological Diseases
Primary Subject Heading:	Neurology
Secondary Subject Heading:	Public health
Keywords:	Adult neurology < NEUROLOGY, Stroke < NEUROLOGY, VASCULAR MEDICINE

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

Title Page

Thrombolysis, Time-to-Treatment and In-Hospital Outcomes Among Young Adults with Ischemic Stroke in China: Findings from a Nationwide Registry Study in China

Hai-Yan Wang¹ *; Hong-Qiu Gu^{2,3} *; Qi Zhou^{2,3}; Ying-Yu Jiang^{2,3}; Xin Yang^{2,3}; Chun-Juan Wang^{2,3}; Xing-Quan Zhao^{4,5}; Yi-Long Wang^{2,4}; Li-Ping Liu⁶; Xia Meng²; Hao Li²; Chelsea Liu⁷; Zi-Xiao Li^{2,3}; Yong-Jun Wang^{2,3}; Yong Jiang² #;

¹Department of Neurology, Beijing Shijitan Hospital, Capital Medical University, Beijing, China

²China National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University, Beijing, China

³National Center for Healthcare Quality Management in Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University, Beijing, China

⁴Vascular Neurology, Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China

⁵Research Unit of Artificial Intelligence in Cerebrovascular Disease, Chinese Academy of Medical Sciences, Beijing, China

⁶Neuro-intensive Care Unit, Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China

⁷Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA

⁸Beijing Key Laboratory of Translational Medicine for Cerebrovascular Disease, Beijing, China

⁹Center for Stroke, Beijing Institute for Brain Disorders, Beijing, China

* Hai-Yan Wang and Hong-Qiu Gu contributed equally to this paper.

#ADDRESS FOR CORRESPONDENCE

Yong Jiang

China National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University

No.119 West Road, Southern Fourth Ring Road, Fengtai District, Beijing, China, 100070

1
2
3
4 Tel: 86-10-59975806

5
6 Email: jiangyong@ncrcnd.org.cn
7
8
9

10
11 **Key words:** ischemic stroke, young stroke, thrombolysis, door-to-needle time
12
13
14
15

16
17 **Word Count:** 2612
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

ABSTRACT

Background and purpose We aimed to determine whether young adults (< 50 years) with acute ischemic stroke (AIS) are more likely to receive intravenous tissue plasminogen activator (IV tPA) and have shorter time to treatment than older stroke patients.

Methods We analyzed data from the Chinese Stroke Center Alliance (CSCA) registry for AIS patients hospitalized between August 2015 and July 2019. Patients were classified into two groups according to age: young adults (< 50 years of age) and older adults (\geq 50 years of age).

Results Of 793 175 patients with AIS admitted to 1471 hospitals, 9.1% (71 860) were young adults. Compared to older adults, a higher proportion of young adults received IV tPA among patients without contraindications (7.2% vs. 6.1%, adjusted odds ratio [aOR] 1.13, 95% confidence interval [CI] 1.10-1.17) and among patients without contraindications and with onset-to-door time \leq 3.5h (23.6 % vs. 19.3%, aOR 1.20, 95% CI 1.15-1.24). We did not observe differences in onset-to-needle time (median hours 2.7h) or door-to-needle time (DNT) (median minutes 60m) between young and older adults. The proportion of DNT \leq 30 minutes, DNT \leq 45 minutes, and DNT \leq 60 minutes in young and older IV tPA treated patients were 16.9% vs 18.8%, 30.2% vs 32.8% and 50.2% vs 54.2%, respectively. Compared to older adults, young adults treated with IV tPA had lower odds of in-hospital mortality (0.5% vs 1.3%,

1
2
3
4 aOR 0.54, 95% CI 0.35-0.82) and higher odds of independent ambulation at discharge
5
6
7 (61.0% vs 53.6%, aOR 1.15, 95% CI 1.08-1.22), and the associations may be partly
8
9 explained by stroke severity measured by NIHSS score.
10
11

12 **Conclusion** Young adults with AIS were more likely to receive IV tPA than older
13
14 adults, though there was no difference between the two groups in time to treatment.
15
16

17 Compared with older adults, young adults may had better in-hospital outcomes.
18
19

20
21
22
23 **Key words:** ischemic stroke, young stroke, thrombolysis, door-to-needle time
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Strengths and limitations of this study

- We used data from a large-scale, nationwide, hospital-based, multicenter quality improvement initiative.
- Multiple regression models adjusted for different levels of covariates were used to check the robustness of the results ;
- Data on intra-arterial therapies, puncture times, door-to-imaging, and follow-up outcomes after discharge were not collected and reported.

ABBREVIATIONS

CSA: Chinese Stroke Association

CSCA: Chinese Stroke Center Alliance

QI: quality improvement

AIS: acute ischemic stroke

BMI: body mass index

mRS: modified Rankin Scale score

aOR: adjusted odds ratios

CI: confidence intervals

IV tPA: intravenous tissue plasminogen activator

IQR: interquartile range

NIHSS: National Institutes of Health Stroke Scale

DNT: door-to-needle time

sICH: symptomatic intracranial hemorrhage

INTRODUCTION

Stroke incidence among adults under 50 years of age has risen in recent years.¹⁻⁵ This creates a significant socioeconomic burden due to high healthcare costs and loss of labor productivity.^{5,6} According to the 2019 Chinese Stroke Statistics, 81.9% of stroke patients had ischemic strokes,⁷ of which young adults constituted 15–18%.⁸ Given this trend, researchers must carefully consider the clinical features and best practices of treatment for strokes in young adults.⁸

Ischemic stroke is a common, preventable, and treatable disease that typically results from thrombotic or thromboembolic blockage of a cerebral artery.⁹ Revascularization therapy plays a major role in the process of saving penumbral tissue from infarction.¹⁰ Tissue plasminogen activator (tPA) is the main intravenous drug approved for the treatment of acute ischemic stroke.¹¹ Treatment of acute occlusive stroke with IV tPA is considered the most regular and important method when given within 4.5 hours of occlusion.^{12,13} While epidemiological studies have been done in other countries regarding IV tPA treatment in young AIS patients, there is limited research on this topic in China.¹³⁻¹⁷

The purpose of this study was to compare the characteristics, IV tPA treatment rates, onset-to-needle time, door-to-needle time (DNT) and in-hospital outcomes of young (<50 years of age) and older (≥ 50 years of age) AIS patients in the Chinese Stroke

1
2
3
4 Center Alliance (CSCA). We hypothesized that young AIS patients would be treated
5
6 more frequently with IV tPA, have shorter treatment time and better in-hospital
7
8 outcomes compared to older adults.
9
10

11 12 13 14 15 **METHODS**

16 17 18 **Data source**

19
20
21
22 CSCA is a national, hospital-based, multicentre, voluntary, multifaceted intervention
23
24 and continuous quality improvement initiative. The data coordinating center of CSCA
25
26 resides at the China National Clinical Research Center for Neurological Diseases
27
28 (NCRCND), Beijing Tiantan Hospital.¹⁸ Trained personnel collected patient
29
30 demographics, medical history, medications, DNT, and in-hospital outcomes, then
31
32 entered this information into a database using a web-based Patient Management Tool
33
34 (Medicine Innovation Research Center, Beijing, China). The tool is characterized by
35
36 predefined logic features, range checks, and user alerts to identify a potentially invalid
37
38 format or value entries and to optimize data quality at the time of entry. Training in
39
40 the use of the tool was provided online and onsite for all users. However, data
41
42 collected by hospitals were not independently audited by external chart review. In
43
44 addition, The China National Clinical Research Center for Neurological Diseases
45
46 serves as the data analysis center and has an agreement to analyze the aggregate
47
48 deidentified data for care quality feedback and research purposes. We abstracted 838
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 229 cases and identified 793 175 patients admitted with ischemic strokes from 2015 to
5
6
7 2019.

10 **Study population**

13 In the first stage, our analyses included patients admitted with AIS within 7 days of
14
15 the onset of symptoms between August 1, 2015 and July 31, 2019 from 1473 hospitals.
16
17 (supplemental material table I)We excluded patients who had in-hospital strokes
18
19 (n=7941, 0.95%), were missing IV tPA information (n=17461, 2.08%), had imprecise
20
21 or undocumented arrival times (n=12), transferred in from an acute care hospital
22
23 (n=1777, 0.212%), or had contraindications to venous thrombolysis within the time
24
25 window (n=17863, 2.13%). This yielded a population of patients with ischemic
26
27 strokes with indications for thrombolysis (n=793175). To analyze DNT and
28
29 in-hospital outcomes of ischemic stroke, we excluded patients treated with IV tPA
30
31 more than 4.5 hours after stroke onset (n=1315, 0.17%) and patients who were not
32
33 treated with IV tPA (n=743719, 93.76%). This yielded a subset of the study
34
35 population that consisted of 48141 AIS patients from 1290 hospitals (Figure 1).
36
37
38
39
40
41
42
43
44
45
46

47 **Outcomes**

48
49
50 The IV tPA treatment rate was assessed among two populations. First, IV tPA rate
51
52 among patients without contraindications to thrombolytic therapy was calculated as
53
54 the number of IV tPA cases divided by the total number of ischemic stroke cases
55
56 without any contraindications to thrombolytic therapy. Then IV tPA rate among
57
58
59
60

1
2
3
4 patients without contraindication to thrombolytic therapy and with onset-to-door time
5
6 ≤ 3.5 h was calculated as the number of IV tPA cases divided by the total number of
7
8 ischemic stroke cases without any contraindications to thrombolytic therapy and
9
10 arrived at a hospital within 3.5 hours after stroke onset. The contraindications were
11
12 defined according to guidelines for the early management of patients with acute
13
14 ischemic stroke from the Heart Association/American Stroke Association and Chinese
15
16 Society of Neurology. DNT was defined as the time between arrival at the emergency
17
18 department (ED) and time of intravenous (IV) thrombolysis, and is an important
19
20 metric in AIS treatment.^{19,20} We analyzed DNT as a binary outcome three times with a
21
22 different cut-off point each time (≤ 30 , ≤ 45 , or ≤ 60 minutes, respectively).
23
24
25
26
27
28
29
30
31
32
33

34 In-hospital outcomes included symptomatic intracranial hemorrhage (sICH),
35
36 in-hospital mortality, and independent ambulation at discharge. sICH was defined as
37
38 intracranial hemorrhage (ICH) within 36 hours of admission, documented by CT or
39
40 MRI, with the treating physician's notes indicating clinical deterioration attributable
41
42 to hemorrhage. Patients who were able to walk < 48 hours after hospital admission
43
44 were considered to have independent ambulation at discharge.
45
46
47
48
49

50 51 **Statistical analysis**

52
53
54 Continuous variables with normal distribution were expressed as mean and SD, and
55
56 those with skewed/non-normal distribution as medians and interquartile ranges (IQR).
57
58
59 Categorical variables were summarised as frequencies and percentages. Because of
60

1
2
3
4 the large sample size, some statistically significant differences may not be clinically
5
6 meaningful. We used absolute standardized differences (ASD) or Hodges–Lehmann
7
8 estimator to compare differences in baseline characteristics between young and older
9
10 adults independent of sample size. An ASD larger than 10% was considered
11
12
13
14
15 meaningful imbalance.²¹

16
17 For outcomes such as IV tPA treatment and in-hospital outcomes, logistic regression
18
19 models were performed to determine adjusted odds ratios (aORs) and 95% confidence
20
21 intervals (CIs). Multivariable models with different level of adjustment were used to
22
23 check the robustness of the results. Covariates in multivariable models including
24
25 gender, insurance status, body mass index (BMI), medical history of prior stroke or
26
27 transient ischemic attack (TIA), coronary artery disease (CAD) or prior myocardial
28
29 infarction (MI), diabetes mellitus, hypertension, smoking status, atrial
30
31 fibrillation/flutter, glycated hemoglobin, diastolic blood pressure, systolic blood
32
33 pressure, medication history (hypoglycemic drugs, antihypertensive drugs, antiplatelet
34
35 drugs, and lipid lowering drugs), and hospital grade.

36
37
38
39
40
41
42
43
44
45
46
47 There were few missing data for most variables, with the exceptions of the in-hospital
48
49 NIHSS score (missing 19.4%), DNT (6.3%), glycated hemoglobin (10.6%) and BMI
50
51 (1.6%). For continuous variables missing less than 15%, the median was used for
52
53 imputation. Since the NIHSS score is a widely used tool for assessing stroke
54
55 severity²² and contributes important information to AIS prognosis,²³ sensitivity
56
57
58
59
60

1
2
3
4 analyses adjusting for the NIHSS score were conducted. In addition, results from
5
6 multiple imputation were also provided.
7
8
9

10
11 All statistical analyses were performed using SAS Version 9.4 (SAS Institute, Cary,
12
13 NC, USA) and the %ggBaseline SAS macro.²⁴ Two-sided p-values of <0.05 were
14
15 considered statistically significant.
16
17
18
19

20 21 **Patient and public involvement**

22
23
24
25 Patients or the public were not involved in the design, or conduct, or reporting, or
26
27 dissemination plans of our research.
28
29

30 31 **RESULTS**

32
33
34 Of 838 229 patients with AIS in the CSCA, 793 175 patients enrolled from 1471
35
36 hospitals were eligible for inclusion in this study. The median age was 67.0 years
37
38 (range: 58.0-75.0) and 62.7% were men. A total of 261 760 (33.0%) patients had
39
40 previous stroke/TIA, 69 810 (8.8%) had coronary artery disease or myocardial
41
42 infarction (CAD/prior MI), 170 638 (21.5%) had diabetes, 510 928 (64.4%) had
43
44 hypertension, 294 708 (37.2%) were smokers, and 40 231 (5.1%) had atrial
45
46 fibrillation/flutter.
47
48
49
50
51
52
53

54 55 **Clinical characteristics**

56
57
58 A total of 71 860 (9.1%) patients were young adults (<50 years) and 721 315 (90.9%)
59
60

1
2
3
4 were older adults (≥ 50 years). The mean age among young adults was 43.8 ± 5.3 years
5
6 and 68.3 ± 10.0 years among older adults. A larger proportion of the young adults were
7
8 men (76.3% vs 61.3%) and did not have health insurance coverage (12.9% vs 5.7%),
9
10 compared to older adults. Young adults had a lower prevalence of cardiovascular risk
11
12 factors compared to older adults, including history of stroke or TIA (22.5% vs 34.0%),
13
14 CAD/prior MI (4.0% vs 9.3%), diabetes mellitus (15.3% vs 22.1%), hypertension
15
16 (53.9% vs 65.5%), and atrial fibrillation (1.2% vs 5.5%). Young adults had a lower
17
18 rate of medication use than older adults, including hypoglycemic drugs (10.9% vs
19
20 17.4%), antihypertensive drugs (33.5% vs 48%), antiplatelet drugs (14.6% vs 21.5%),
21
22 and lipid lowering drugs (11.4% vs 15.3%). However, diastolic blood pressure in
23
24 young adults was significantly higher than that of older adults (mean \pm SD 92.3 ± 16.1
25
26 vs mean \pm SD 86.5 ± 13.5), and young adults had a statistically higher mean BMI than
27
28 older adults (mean \pm SD 24.9 ± 4.8 vs mean \pm SD 23.9 ± 4.2). The proportion of young
29
30 adults who smoked was also higher than that of older adults (49.9% vs 35.9%) (Table
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
1).

Table 1. Baseline characteristics of young and old ischemic stroke patients

Baseline characteristics	Total (N=793175 [100%])	Young adults (< 50 years) (N=71860 [9.1%])	Old adults (≥ 50 years) (N=721315 [90.9%])	ASD (%) / H-L Estimator*
Patient characteristics				
Age, years	66.1 \pm 12.0	43.8 \pm 5.3	68.3 \pm 10.0	306.1
Male, n (%)	496960 (62.7)	54850 (76.3)	442110 (61.3)	32.8
Insurance status, n (%)				
UEBMI	225940 (28.5)	19160 (26.7)	206780 (28.7)	4.5
URBMI	149839 (18.9)	12393 (17.2)	137446 (19.1)	4.9

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

NRCMS	333979 (42.1)	27587 (38.4)	306392 (42.5)	8.4
Self-pa	50727 (6.4)	9263 (12.9)	41464 (5.7)	25.0
Other	32690 (4.1)	3457 (4.8)	29233 (4.1)	3.4
Arrive mode, n (%)				
Ambulance	89484 (11.3)	7170 (10.0)	82314 (11.4)	4.5
Private car	372727 (47.0)	33340 (46.4)	339387 (47.1)	1.4
Taxi	68801 (8.7)	6743 (9.4)	62058 (8.6)	2.8
Bicycle or tricycle	7237 (0.9)	577 (0.8)	6660 (0.9)	1.1
Helicopter	338 (0.0)	27 (0.0)	311 (0.0)	
Mobile stroke unit	246 (0.0)	24 (0.0)	222 (0.0)	
Other	254342 (32.1)	23979 (33.4)	230363 (31.9)	3.2
Medical history, n (%)				
Previous stroke/TIA	261760 (33.0)	16197 (22.5)	245563 (34.0)	25.8
CAD/prior MI	69810 (8.8)	2906 (4.0)	66904 (9.3)	21.4
Diabetes	170638 (21.5)	10985 (15.3)	159653 (22.1)	17.5
Peripheral vascular disease	13512 (1.7)	718 (1.0)	12794 (1.8)	6.8
Hypertension	510928 (64.4)	38722 (53.9)	472206 (65.5)	23.8
Smoking [†]	294708 (37.2)	35848 (49.9)	258860 (35.9)	28.6
Atrial fibrillation/flutter	40231 (5.1)	886 (1.2)	39345 (5.5)	24.1
Dyslipidemia	60605 (7.6)	5861 (8.2)	54744 (7.6)	2.2
Carotid stenosis	10161 (1.3)	509 (0.7)	9652 (1.3)	6.0
Medication history, n (%)				
Anticoagulants	31326 (3.9)	2394 (3.3)	28932 (4.0)	3.7
Hypoglycemic drugs	133244 (16.8)	7802 (10.9)	125442 (17.4)	18.7
Antihypertensive drugs	370017 (46.7)	24065 (33.5)	345952 (48.0)	29.8
Antiplatelet drugs	165771 (20.9)	10482 (14.6)	155289 (21.5)	18.0
Lipid lowering drugs	118827 (15.0)	8171 (11.4)	110656 (15.3)	11.5
NIHSS score in hospital [‡]	3.0 (2.0–6.0)	3.0 (1.0–5.0)	3.0 (2.0–6.0)	
Biochemical Indicators				
Glycated hemoglobin [§] , %	5.8 (5.3–6.5)	5.7 (5.2–6.1)	5.8 (5.3–6.5)	
BMI	24.0±4.3	24.9±4.8	23.9±4.2	22.2
Homocysteine [#] , μmol/L	13.9 (10.4–19.1)	13.4 (10.0–19.0)	13.9 (10.5–19.1)	
Systolic blood pressure ^{* *} , mmHg	150.0±23.0	147.9±24.4	150.2±22.8	9.7
Diastolic blood pressure ^{††} , mmHg	87.0±13.9	92.3±16.1	86.5±13.5	39.0
Hospital characteristics, n (%)				
Hospital level				
Secondary hospital	303790 (38.3)	23993 (33.4)	279797 (38.8)	11.3
Tertiary hospital	489385 (61.7)	47867 (66.6)	441518 (61.2)	11.3
Hospital region				
Eastern China	365579 (46.1)	32744 (45.6)	332835 (46.1)	1.0

Central China	262618 (33.1)	24477 (34.1)	238141 (33.0)	2.3
Western China	164978 (20.8)	14639 (20.4)	150339 (20.8)	1.0

Abbreviations: UEBMI, urban employee basic medical insurance; URBMI, urban resident basic medical insurance; NRCMS, new rural cooperative medical scheme; TIA, transient ischemic attack; CAD, coronary artery disease; MI, myocardial infarction; SD: standard deviation; IQR, interquartile range; NIHSS, National Institutes of Health Stroke Scale; ASD, absolute standardized difference.

*HL estimator, Hodges–Lehmann estimator; an absolute standardized difference (%) >10% indicates meaningful imbalance between 2 groups.

†Smoking: having smoking experience or behaviors.

‡Information was missing for N=154052 patients (19.4%).

§Information was missing for N=84393 patients (10.6%); median was used for imputation.

|| Information was missing for N=12698 patients (1.6%); median was used for imputation.

#Information was missing for N= 35781 patients (4.5%).

** Information was missing for N=245 patients (≈0.0%); median was used for imputation.

††Information was missing for N=251 patients (≈0.0%); median was used for imputation.

IV tPA treatment rates

Young adults were treated more frequently with IV tPA than older adults among patients without contraindications to thrombolysis (7.2% vs 6.1%, aOR 1.13, 95% CI 1.10-1.17) and among patients without contraindication and with onset-to-door time \leq 3.5h (23.6 % vs. 19.3%, aOR 1.20, 95% CI 1.15-1.24). Data from sensitivity analyses showed consistent results.(Table 2)

Table 2. Multivariable analysis of IV tPA treatment by age group

Treatment	Rate of IV-tPA	aOR (95% CI) from model 1	aOR (95% CI) from model 2	aOR (95% CI) from model 3	aOR (95% CI) from model 4
IV tPA among patients without contraindications	49456/793175 (6.2)				
Young adults	5181/71860 (7.2)	1.19 (1.15-1.22)	1.13 (1.10-1.17)	1.20 (1.16-1.24)	1.19(1.15-1.22)
Old adults	44275/721315 (6.1)	1.00	1.00	1.00	1.00
IV tPA among patients without contraindication and with onset-to-door time \leq 3.5h	45842/232905(19.7)				
Young adults	4768/20191 (23.6)	1.29 (1.25-1.34)	1.20 (1.15-1.24)	1.24 (1.20-1.29)	1.23(1.19-1.28)
Old adults	41074/212714 (19.3)	1.00	1.00	1.00	1.00

Abbreviations: CI, confidence interval; IV tPA, intravenous recombinant tissue plasminogen activator; OR, odds ratio.

Model 1: Logistic regression model without adjustment.

Model 2: adjusted for gender, insurance, BMI, previous stroke/TIA, previous CAD/prior MI, diabetes, hypertension, have smoking experience or behavior, atrial fibrillation/flutter, glyated, hemoglobin, diastolic blood pressure, hypoglycemic drugs, antihypertensive drugs, antiplatelet drugs, lipid-lowering drugs, and hospital level.

Model 3: adjusted for were in-hospital NIHSS score, gender, insurance, BMI, previous stroke/TIA, previous CAD/prior MI, diabetes, hypertension, have smoking experience or behavior, atrial fibrillation/flutter, glyated hemoglobin, diastolic blood pressure, hypoglycemic drugs, antihypertensive drugs, antiplatelet drugs, lipid-lowering drugs, and hospital level. Patients (N= 154052) with missing values on NIHSS score were not included in this analysis.

model 4: results from multiple imputation.

Treatment time

While young adults were more likely to receive IV tPA, there was no significant difference in onset-to-needle time (median 2.7 hours, IQR 2.0–3.5 for both groups) and DNT (median 60.0 minutes, IQR 42.0–90.0 vs median 60.0 minutes, IQR 36.0–84.0) among young and older adults. DNT was also analyzed as a binary outcome at three levels: DNT \leq 30, DNT \leq 45, and DNT \leq 60 minutes. There were no significant differences between the two groups on any DNT level (16.9% vs 18.8%; 30.2% vs 32.8%; 50.2% vs 54.2%) (Table 3).

Table 3. Treatment time in young and old ischemic stroke patients treated with IV tPA

Measures	Total (N=48141 [100%])	Young adults (< 50 years) (N=5044 [10.5%])	Old adults (\geq 50 years) (N=43097 [89.5%])	ASD (%)/H-L Estimator *
Onset-to-needle time [†] ,h	2.7 (2.0–3.5)	2.7 (2.0–3.5)	2.7 (2.0–3.5)	
DNT [‡] ,min	60.0 (36.0–84.0)	60.0 (42.0–90.0)	60.0 (36.0–84.0)	
Treatment time				
DNT \leq 30 minutes	8938 (18.6)	850 (16.9)	8088 (18.8)	5.0
DNT \leq 45 minutes	15637 (32.5)	1521 (30.2)	14116 (32.8)	5.6

DNT≤60 minutes	25884 (53.8)	2531 (50.2)	23353 (54.2)	8.0
----------------	--------------	-------------	--------------	-----

Abbreviations: CI=confidence interval; IV tPA, intravenous recombinant tissue plasminogen activator; DNT, door-to-needle time; ASD, absolute standardized difference.

*HL estimator, Hodges–Lehmann estimator; an absolute standardized difference (%) >10% indicates meaningful imbalance between 2 groups.

†Onset-to-needle time was missing for 3818 (7.9%) patients, with 431(8.5%) in age <50 and 3387(7.9%) in ≥ 50 groups.

‡DNT was missing for 3027(6.3%) patients, with 342 (6.8%) in age <50 and 2685(6.2%) in ≥ 50 groups.

In-hospital outcomes

In-hospital outcomes including sICH, in-hospital mortality, and independent ambulation at discharge were summarized in Table 4. Multiple logistic regression with adjustments of unbalanced covariates (ASD% >10% in Supplemental Table II) showed that young adults had non-significantly lower rates of sICH (0.5% vs 0.9%, aOR=0.74, 95% CI 0.49-1.11) than older adults. However, young adults had significantly lower rates of in-hospital mortality (0.5% vs 1.3%, aOR=0.54, 95% CI 0.35-0.82) and were more likely to be independently ambulating at discharge (61.0% vs 53.6%, aOR=1.15, 95% CI 1.08-1.22).

In sensitivity analyses adjusted for NIHSS scores, young adults had non-significantly lower odds of sICH (aOR=0.77, 95%CI 0.5-1.18), in-hospital mortality (aOR=0.70, 95%CI 0.46-1.09), and a neutral association with independent ambulation at discharge (aOR=1.00, 95% CI 0.93-1.08). Sensitivity analysis using different age cut-off point (<35 years and ≥ 35 years) showed consistent results with primary analysis

1
2
3
4 (supplemental material table III). But when we used another age cut of point (<45
5
6 years and ≥ 45 years), we had a lower sICH rate (aOR=0.44, 95% CI 0.19-0.99) in
7
8
9 the young group (supplemental material table IV).
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Table 4. In-hospital outcomes in young and old ischemic stroke patients treated with IV tPA

Outcome	Rate of outcomes	aOR (95% CI) from model 1	aOR (95% CI) from model 2	aOR (95% CI) from model 3	aOR (95% CI) from model 4
sICH	414/48141 (0.9)				
Young adults	26/5044(0.5)	0.57 (0.38-0.85)	0.74 (0.49-1.11)	0.77 (0.5-1.18)	0.79(0.52-1.20)
Old adults	388/43097(0.9)	1.00	1.00	1.00	1.00
In-hospital mortality	579/48141 (1.2)				
Young adults	24/5044(0.5)	0.37 (0.24-0.55)	0.54 (0.35-0.82)	0.70 (0.46-1.09)	0.65(0.43-1.00)
Old adults	555/43097(1.3)	1.00	1.00	1.00	1.00
Independent ambulation at discharge	26175/48141 (54.4)				
Young adults	3079/5044(61.0)	1.36 (1.28-1.44)	1.15 (1.08-1.22)	1.00 (0.93-1.08)	1.02(0.96-1.10)
Old adults	23096/43097(53.6)	1.00	1.00	1.00	1.00

Abbreviations: CI, confidence interval; IV tPA, intravenous recombinant tissue plasminogen activator; OR, odds ratio.

Model 1: Logistic regression model without adjustment.

Model 2: Adjusted for gender, insurance, BMI, previous stroke/TIA, previous CAD/prior MI, diabetes, hypertension, have smoking experience or behavior, atrial fibrillation/flutter, glycated hemoglobin, diastolic blood pressure, systolic blood pressure, hypoglycemic drugs, antihypertensive drugs, antiplatelet drugs, and lipid-lowering drugs.

Model 3: Adjusted for in-hospital NIHSS score, gender, insurance, BMI, previous stroke/TIA, previous CAD/prior MI, diabetes, hypertension, have smoking experience or behavior, atrial fibrillation/flutter, glycated hemoglobin, diastolic blood pressure, blood pressure, hypoglycemic drugs, antihypertensive drugs, antiplatelet drugs, and lipid-lowering drugs. Patients (N= 2503) with missing values on NIHSS score were not included in this analysis.

model 4: results from multiple imputation.

DISCUSSION

In this hospital-based observational study of 793 175 AIS patients, we found that young adults (<50 years of age) were more likely to be treated with IV tPA than older adults (7.2% vs 6.1%), which was consistent with our hypothesis. Our study demonstrated that young stroke patients had fewer comorbidities (previous stroke/TIA, previous CAD/prior MI, diabetes, hypertension, and atrial fibrillation/flutter) at baseline, which may compel providers to feel more secure in administering IV tPA to this group of patients. Even though we did not observe a difference in DNT between age groups, we found that young adults had more favorable in-hospital outcomes than older adults, including lower odds of sICH, in-hospital mortality and higher odds of independent ambulation at discharge. However, after adjusting for NIHSS scores, the differences were not significant. Therefore, the benefit among young adults may be explained by stroke severity measured by NIHSS score.

We chose 50 as the cut-off age because several important international studies on thrombolytic therapy in young people also set the cut-off age at 50.^{15,16} Using the same cut-off age value would benefit the comparison with other studies and also have advantages for potential systematic review and meta-analysis.

IV tPA thrombolytic therapy is considered to be the standard therapy in patients with acute ischemic stroke. However, its use has been studied primarily in adults over age

1
2
3
4 50.¹⁶ Given increasing evidence in the literature that thrombolytic therapy rarely
5
6 causes hemorrhages in patients with stroke-mimicking conditions, providers may also
7
8 feel more comfortable administering IV tPA to young adults when it is uncertain
9
10 whether a stroke or a stroke mimic had occurred.²⁵ Our research also supports this
11
12 conclusion. Young adults had similar time to treatment and were more likely to be
13
14 treated than older adults, which may reflect increased awareness among patients and
15
16 clinicians that stroke is a potentially fatal disease affecting people of all ages.
17
18
19
20
21
22
23
24
25

26 The relationship between time to treatment and mortality was first recognized in
27
28 clinical studies.^{26,27} The importance of this metric was reemphasized in the 2004
29
30 American College of Cardiology/American Heart Association practice guidelines,
31
32 which stated that DNT targets “should not be perceived as an average performance
33
34 standard but as a goal that an early treatment system in every hospital should seek for
35
36 every appropriate patient”.²⁸ Consistent with a prior analysis of SITS-ISTR showing
37
38 no difference in median door-to-needle times between patients 18 to 50 and >50 years
39
40 of age, there was also not an obvious differentiation in treatment among young or
41
42 older adults in our study.¹⁵ However, a prior study by Dodds and colleagues found
43
44 that young adults (18-40 years) with AIS were more likely to experience a delay in
45
46 evaluation and treatment.¹³ Our definition of young adults (age <50 years) differs
47
48 from theirs (age 18–40 years) and is more applicable in China, which may also
49
50 explain why we did not find differences in treatment times between the two groups.²⁹
51
52
53
54
55
56
57
58
59
60

1
2
3
4 Another explanation for the lack of differences in treatment times between the two
5
6 groups may be that DNT mainly depends on hospital level and treatment process
7
8 rather than age.
9
10

11
12
13
14
15 In our study, we observed a higher rate of sICH and in-hospital mortality among older
16
17 adults treated with IV tPA, though the difference was not significant adjusted for
18
19 NIHSS scores. We cannot entirely separate young age from lower NIHSS score, as
20
21 young patients are highly correlated with lower NIHSS scores in clinical practise
22
23 (4.0±4.5 vs. 4.9±5.3, the Rank Biserial correlation coefficient in this study is 0.10,
24
25 p<0.001). Therefore, the associations may be partly explained by stroke severity
26
27 measured by NIHSS score. Although we do not find significant differences between
28
29 these two groups, we do see a trend towards better outcomes in young people. One
30
31 possible explanation is that younger stroke patients have fewer comorbidities in their
32
33 medical history, such as previous stroke or TIA, CAD/MI, diabetes mellitus,
34
35 hypertension, and atrial fibrillation, as well as milder strokes, all of which are
36
37 associated with better outcomes.³⁰ Other factors favoring recovery in young stroke
38
39 patients include greater brain plasticity and more robust family and social support.³¹
40
41
42
43
44
45
46
47
48
49
50

51
52
53 There are several limitations in our study. Since hospital participation in the CSCA is
54
55 voluntary, participating hospitals are more likely to be larger, tertiary centers with a
56
57 myriad of resources that smaller hospitals do not have access to. We recognize that
58
59
60

1
2
3
4 findings from CSCA may not be generalizable to AIS patients admitted to hospitals
5
6 outside of the CSCA. Second, we did not report data on intra-arterial (IA) therapies
7
8 and puncture times because only a very small number of patients in our study received
9
10 thrombectomy. We also did not have door-to-imaging data to support the study and
11
12 there was a relatively high proportion of missing DNT values (6.3% overall, 6.8% in
13
14 young and 6.2% in older patients). However, we did not observe a significant
15
16 difference in DNTs between young and older AIS patients. Lastly, although we
17
18 provided some possible explanation for the differences between young and old adults
19
20 group, further researches are needed to explore the detailed mechanism.
21
22
23
24
25
26
27
28
29
30

31 **CONCLUSION**

32
33
34
35 In summary, young adults with AIS are more likely to receive IV tPA than older
36
37 adults, but there is no difference between the two groups in time to treatment. Young
38
39 adults may have better in-hospital outcomes compared with older adults, suggesting
40
41 favorable effects of treatment with IV tPA.
42
43
44
45
46
47
48

49 **ACKNOWLEDGEMENTS**

50
51
52 We thank the staff and participants of the CSCA (Chinese Stroke Center Alliance)
53
54 studies for their contribution.
55
56
57
58
59
60

CONTRIBUTORS

Conceived and led the project: XZ, YW, ZL, YW and YJ. Conception and design:

HW, HG, YW and YJ. Data collection and analysis: HW, XY, CW, HG and QZ.

Interpret the data: LL, XM and HL. Drafting the article and revising the content: HW,

HG, CL, JY and ZL. All authors approved the final version of the manuscript.

FUNDING

The Chinese Stroke Center Alliance program was supported by grants from the

Ministry of Science and Technology and the Ministry of Health of the People's

Republic of China (National Key R&D Program of China, Code: 2016YFC0901001,

2017YFC1310901, 2016YFC0901002, 2017YFC1307905, 2015BAI12B00), Beijing

Talents Project (2018A13, 2018000021223ZK03), CAMS Innovation Fund for

Medical Sciences (2019-I2M-5-029), Beijing Municipal Committee of Science and

Technology (Z201100005620010), Beijing Natural Science Foundation (Z200016).

COMPETING INTERESTS

None declared.

PATIENT CONSENT FOR PUBLICATION

Not required.

ETHICS APPROVAL

This study received approval from the Institutional Review Board/Ethics Committee of Beijing Tiantan Hospital, Capital Medical University with approval number KY 2018-061-02. Participating hospitals received research approval to collect data in CSCA without requiring individual patient informed consent under the common rule or a waiver of authorisation and exemption from their Institutional Review Board.

DATA AVAILABILITY STATEMENT

Data are available upon reasonable request. The data that support the findings of this study are available from the corresponding author upon reasonable request and after clearance by the local ethics committee.

REFERENCES

1. Béjot Y, Bailly H, Durier J, et al. Epidemiology of stroke in Europe and trends for the 21st century. *Presse Med* 2016;45:e391-8. doi: 10.1016/j.lpm.2016.10.003 [published Online First: 2016/11/07]
2. Hathidara MY, Saini V, Malik AM. Stroke in the young: A global update. *Current neurology and neuroscience reports* 2019;19:91. doi: 10.1007/s11910-019-1004-1 [published Online First: 2019/11/27]
3. Rutten-Jacobs LC, Maaijwee NA, Arntz RM, et al. Risk factors and prognosis of

- 1
2
3
4 young stroke. The FUTURE study: a prospective cohort study. Study rationale and
5
6 protocol. *BMC Neurol* 2011;11:109. doi: 10.1186/1471-2377-11-109 [published
7
8 Online First: 2011/09/22]
9
10
11
12 4. George MG. Risk Factors for Ischemic Stroke in Younger Adults: A Focused
13
14 Update. *Stroke* 2020;51:729-35. doi: 10.1161/strokeaha.119.024156 [published
15
16 Online First: 2020/02/23]
17
18
19
20 5. Maaijwee NA, Rutten-Jacobs LC, Schaapsmeeders P, et al. Ischaemic stroke in
21
22 young adults: risk factors and long-term consequences. *Nat Rev Neurol*
23
24 2014;10:315-25. doi: 10.1038/nrneurol.2014.72 [published Online First: 2014/04/30]
25
26
27
28 6. Feigin VL, Roth GA, Naghavi M, et al. Global burden of stroke and risk factors in
29
30 188 countries, during 1990–2013: a systematic analysis for the Global Burden of
31
32 Disease Study 2013. *The Lancet Neurology* 2016;15:913-24. doi:
33
34 10.1016/s1474-4422(16)30073-4
35
36
37
38
39 7. Wang Y-J, Li Z-X, Gu H-Q, et al. China Stroke Statistics 2019: A Report From the
40
41 National Center for Healthcare Quality Management in Neurological Diseases, China
42
43 National Clinical Research Center for Neurological Diseases, the Chinese Stroke
44
45 Association, National Center for Chronic and Non-communicable Disease Control
46
47 and Prevention, Chinese Center for Disease Control and Prevention and Institute for
48
49 Global Neuroscience and Stroke Collaborations. *Stroke and Vascular Neurology*
50
51 2020;5:211-39. doi: 10.1136/svn-2020-000457
52
53
54
55
56
57
58 8. Singhal AB, Biller J, Elkind MS, et al. Recognition and management of stroke in
59
60

- 1
2
3
4 young adults and adolescents. *Neurology* 2013;81:1089-97. doi:
5
6 10.1212/WNL.0b013e3182a4a451 [published Online First: 2013/08/16]
7
8
9 9. Peña-Martínez C, Durán-Laforet V, García-Culebras A, et al. Pharmacological
10
11 Modulation of Neutrophil Extracellular Traps Reverses Thrombotic Stroke tPA
12
13 (Tissue-Type Plasminogen Activator) Resistance. *Stroke* 2019;50:3228-37. doi:
14
15 10.1161/strokeaha.119.026848 [published Online First: 2019/09/19]
16
17
18 10. Martínez-Sánchez P, Díez-Tejedor E, Fuentes B, et al. Systemic Reperfusion
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
11. Powers WJ, Rabinstein AA, Ackerson T, et al. Guidelines for the Early Management of Patients With Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. *Stroke* 2019;50:e344-e418. doi:10.1161/STR.0000000000000211
12. Berge E, Whiteley W, Audebert H, et al. European Stroke Organisation (ESO) guidelines on intravenous thrombolysis for acute ischaemic stroke. *Eur Stroke J* 2021;6:I-LXII. doi: 10.1177/2396987321989865
13. Dodds JA, Xian Y, Sheng S, et al. Thrombolysis in young adults with stroke: Findings from Get With The Guidelines-Stroke. *Neurology* 2019;92:e2784-92. doi: 10.1212/wnl.0000000000007653 [published Online First: 2019/05/17]
14. Papavasileiou V, Goldstein LB. Thrombolysis in young adults with acute ischemic

1
2
3
4 stroke. *Neurology* 2019;92:1129-30. doi: 10.1212/wnl.0000000000007651
5

6
7 15. Toni D, Ahmed N, Anzini A, et al. Intravenous thrombolysis in young stroke
8
9 patients: results from the SITS-ISTR. *Neurology* 2012;78:880-7. doi:
10
11 10.1212/WNL.0b013e31824d966b [published Online First: 2012/03/10]
12
13

14
15 16. Poppe AY, Buchan AM, Hill MD. Intravenous thrombolysis for acute ischaemic
16
17 stroke in young adult patients. *Can J Neurol Sci* 2009;36:161-7. doi:
18
19 10.1017/s031716710012027x [published Online First: 2009/04/22]
20
21
22

23
24 17. Shi J, Cao Y, You S, et al. Young Stroke Patients Treated with Intravenous
25
26 Thrombolysis have a More Favorable Outcome and Mortality Compared with Older
27
28 Patients. *Curr Neurovasc Res* 2017;14:141-48. doi:
29
30 10.2174/1567202614666170328095431 [published Online First: 2017/03/31]
31
32
33

34
35 18. Wang Y, Li Z, Wang Y, et al. Chinese Stroke Center Alliance: a national effort to
36
37 improve healthcare quality for acute stroke and transient ischaemic attack: rationale,
38
39 design and preliminary findings. *Stroke Vasc Neurol* 2018;3:256-62. doi:
40
41 10.1136/svn-2018-000154 [published Online First: 2019/01/15]
42
43
44

45
46 19. Hsieh CY, Chen WF, Chen CH, et al. Efforts to reduce the door-to-needle time of
47
48 thrombolysis in acute ischemic stroke: video-assisted therapeutic risk communication.
49
50 *J Formos Med Assoc* 2014;113:929-33. doi: 10.1016/j.jfma.2013.11.012 [published
51
52 Online First: 2014/01/15]
53
54

55
56 20. van Tuijn CF, Luitse JS, van der Valk M, et al. Reduction of the door-to-needle
57
58 time for administration of antibiotics in patients with a severe infection: a tailored
59
60

1
2
3
4 intervention project. *Neth J Med* 2010;68:123-7.
5

6
7 21. Austin PC. Balance diagnostics for comparing the distribution of baseline
8
9 covariates between treatment groups in propensity-score matched samples. *Stat Med*
10
11 2009;28:3083-107. doi: 10.1002/sim.3697 [published Online First: 2009/09/17]
12
13

14
15 22. Habib M, Karim ASMR, Hossain MM, et al. Assessment of Initial Stroke Severity
16
17 by National Institute Health Stroke Scale (NIHSS) Score at Admission. *Journal of*
18
19 *Dhaka Medical College* 2018;26:90-93. doi: 10.3329/jdmc.v26i2.38765
20
21

22
23 23. Chen X, Zhan X, Chen M, et al. The prognostic value of combined NT-pro-BNP
24
25 levels and NIHSS scores in patients with acute ischemic stroke. *Intern Med*
26
27 2012;51:2887-92. doi: 10.2169/internalmedicine.51.8027 [published Online First:
28
29 2012/10/16]
30
31

32
33 24. Gu HQ, Li DJ, Liu C, et al. %ggBaseline: a SAS macro for analyzing and
34
35 reporting baseline characteristics automatically in medical research. *Ann Transl Med*
36
37 2018;6:326. doi: 10.21037/atm.2018.08.13 [published Online First: 2018/10/27]
38
39

40
41 25. Zinkstok SM, Engelter ST, Gensicke H, et al. Safety of thrombolysis in stroke
42
43 mimics: results from a multicenter cohort study. *Stroke* 2013;44:1080-4. doi:
44
45 10.1161/STROKEAHA.111.000126
46
47

48
49 26. Cannon CP, Gibson CM, Lambrew CT, et al. Relationship of
50
51 symptom-onset-to-balloon time and door-to-balloon time with mortality in patients
52
53 undergoing angioplasty for acute myocardial infarction. *Jama* 2000;283:2941-7. doi:
54
55 10.1001/jama.283.22.2941 [published Online First: 2000/06/24]
56
57
58
59
60

- 1
2
3
4 27. Schull MJ, Vermeulen M, Donovan L, et al. Can the wrong statistic be bad for
5
6 health? Improving the reporting of door-to-needle time performance in acute
7
8 myocardial infarction. *Am Heart J* 2005;150:583-7. doi: 10.1016/j.ahj.2005.03.061
9
10 [published Online First: 2005/09/20]
11
12
13
14
15 28. Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the
16
17 management of patients with ST-elevation myocardial infarction--executive summary:
18
19 a report of the American College of Cardiology/American Heart Association Task
20
21 Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for
22
23 the Management of Patients With Acute Myocardial Infarction). *Circulation*
24
25 2004;110:588-636. doi: 10.1161/01.Cir.0000134791.68010.Fa [published Online First:
26
27 2004/08/04]
28
29
30
31
32
33
34 29. Xiaobing Z SH, Li'an H. Clinical investigation of stroke in young and
35
36 middle-aged adults. *Cerebrovascular Diseases Foreign Medical Sciences*
37
38 2004;012:354-7.
39
40
41
42 30. Arnold M, Halpern M, Meier N, et al. Age-dependent differences in demographics,
43
44 risk factors, co-morbidity, etiology, management, and clinical outcome of acute
45
46 ischemic stroke. *Journal of Neurology* 2008;255:1503-07. doi:
47
48 10.1007/s00415-008-0949-9
49
50
51
52
53 31. Popa-Wagner A, Carmichael ST, Kokaia Z, et al. The response of the aged brain
54
55 to stroke: too much, too soon? *Curr Neurovasc Res* 2007;4:216-27. doi:
56
57 10.2174/156720207781387213 [published Online First: 2007/08/19]
58
59
60

1
2
3
4
5 **Figure legend**
6

7 Figure 1. Study flowchart for patients identification.

8 Abbreviations: IV tPA, intravenous tissue plasminogen activator.
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Source population

Admission (N=838229)
Hospital (N=1473)
August 1, 2015 to July 31, 2019

Excluded (n=45054)

- In-hospital stroke (7941)
- Missing IV tPA information (17461)
- Missing arrival time (12)
- Transferred in from acute care hospital (1777)
- Contraindications to venous thrombolysis within a time window (17863)

Analysis of outcomes in all ischemic stroke

Admission (N=793175)
Hospital (N=1471)

Excluding (n=745034)

- Treated with tPA but >4.5h (1315) Not
- treated with tPA (743719)

Analysis of treatment times, and outcomes in patients treated with tPA within 4.5 hours

Admission (N=48141)
Hospital (N=1290)

Supplemental Material

1
2 Table I . Distribution of hospitals in our study

Hospital region	Province or Municipality	Number of hospitals (N=676)	Hospital region	Province or Municipality	Number of hospitals (N=401)	Hospital region	Province or Municipality	Number of hospitals (N=394)
Eastern China	Beijing	16	Central China	Jilin	32	Western China	Inner Mongolia	23
	Tianjin	13		Heilongjiang	41		Guangxi	49
	Hebei	143		Shanxi	44		Chongqing	16
	Liaoning	53		Anhui	29		Sichuan	125
	Shanghai	16		Jiangxi	25		Guizhou	23
	Jiangsu	93		Henan	157		Yunnan	52
	Zhejiang	86		Hubei	39		Tibet	1
	Fujian	52		Hunan	34		Shaanxi	41
	Shandong	81					Gansu	33
Guangdong	113			Qinghai	9			
Hainan	10			Ningxia	5			
				Xinjiang	17			

Table II. Baseline characteristics of young and old ischemic stroke patients with IV tPA treatment

Baseline characteristics	Total (N=48141 [100%])	Young adults (< 50 years) (N=5044 [10.5%])	Old adults (≥50 years) (N=43097 [89.5%])	ASD*
Patient characteristics				
Age, years	65.2±12.1	43.4±5.6	67.8±9.8	305.7
Male, n (%)	31456 (65.3)	3961 (78.5)	27495 (63.8)	32.9
Insurance status, n (%)				
UEBMI	15948 (33.1)	1609 (31.9)	14339 (33.3)	3.0
URBMI	9813 (20.4)	913 (18.1)	8900 (20.7)	6.6
NRCMS	16442 (34.2)	1495 (29.6)	14947 (34.7)	10.9
Self-pa	4083 (8.5)	813 (16.1)	3270 (7.6)	26.5
Other	1855 (3.9)	214 (4.2)	1641 (3.8)	2.0
Arrive mode, n (%)				
Ambulance	14364 (29.8)	1352 (26.8)	13012 (30.2)	7.5
Private car	21213 (44.1)	2240 (44.4)	18973 (44.0)	0.8
Taxi	2539 (5.3)	357 (7.1)	2182 (5.1)	8.4
Bicycle or tricycle	118 (0.2)	7 (0.1)	111 (0.3)	4.5
Helicopter	14 (0.0)	1 (0.0)	13 (0.0)	
Mobile stroke unit	31 (0.1)	4 (0.1)	27 (0.1)	0.0
Other	9862 (20.5)	1083 (21.5)	8779 (20.4)	2.7
Medical history, n (%)				
Previous stroke/TIA	12339 (25.6)	830 (16.5)	11509 (26.7)	25.0
CAD/prior MI	4737 (9.8)	240 (4.8)	4497 (10.4)	21.3
Diabetes	8477 (17.6)	516 (10.2)	7961 (18.5)	23.8
Peripheral vascular disease	628 (1.3)	31 (0.6)	597 (1.4)	8.0
Hypertension	28815 (59.9)	2283 (45.3)	26532 (61.6)	33.1
Smoking [†]	18835 (39.1)	2567 (50.9)	16268 (37.7)	26.8
Atrial fibrillation/flutter	5692 (11.8)	138 (2.7)	5554 (12.9)	38.7
Dyslipidemia	3195 (6.6)	351 (7.0)	2844 (6.6)	1.6
Carotid stenosis	454 (0.9)	22 (0.4)	432 (1.0)	7.2
Medication history, n (%)				
Anticoagulants	1779 (3.7)	150 (3.0)	1629 (3.8)	4.4
Hypoglycemic drugs	6404 (13.3)	330 (6.5)	6074 (14.1)	25.2
Antihypertensive drugs	20099 (41.8)	1302 (25.8)	18797 (43.6)	38.1
Antiplatelet drugs	7882 (16.4)	467 (9.3)	7415 (17.2)	23.5
Lipid lowering drugs	5614 (11.7)	382 (7.6)	5232 (12.1)	15.1
NIHSS score in hospital [‡]	7.9±6.5	6.4±5.3	8.0±6.6	26.7
Biochemical Indicators				
Glycated hemoglobin [§] , %		5.6 (5.1–6.0)	5.8 (5.3–6.5)	
BMI	23.6±4.2	24.9±5.5	23.4±4.0	31.2
Homocysteine [#] , μmol/L	13.3 (10.0–18.5)	12.7 (9.6–18.9)	13.3 (10.1–18.5)	
Systolic blood pressure ^{**} , mmHg	152.5±23.8	148.3±24.6	153.0±23.7	19.5
Diastolic blood pressure ^{††} , mmHg	87.6±14.5	92.1±16.1	87.1±14.2	32.9

(Continued)

Table 2. Baseline characteristics of young and old ischemic stroke patients with IV tPA treatment

Baseline characteristics	Total (N=48141 [100%])	Young adults (< 50 years) (N=5044 [10.5%])	Old adults (≥50 years) (N=43097 [89.5%])	ASD*
Hospital characteristics, n (%)				
Hospital level				
Secondary hospital	16479 (34.2)	1735 (34.4)	14744 (34.2)	0.4
Tertiary hospital	31662 (65.8)	3309 (65.6)	28353 (65.8)	0.4
Hospital region				
Eastern China	26410 (54.9)	2792 (55.4)	23618 (54.8)	1.2
Central China	15024 (31.2)	1630 (32.3)	13394 (31.1)	2.6
Western China	6707 (13.9)	622 (12.3)	6085 (14.1)	5.3

Abbreviations: IV tPA, intravenous recombinant tissue plasminogen activator; UEBMI, urban employee basic medical insurance; URBMI, urban resident basic medical insurance; NRCMS, new rural cooperative medical scheme; TIA, transient ischemic attack; CAD, coronary artery disease; MI, myocardial infarction; SD, standard deviation; IQR, interquartile range; NIHSS, National Institutes of Health Stroke Scale; ASD, absolute standardized difference.

*: An absolute standardized difference >10% indicates meaningful imbalance between 2 groups.

†: Smoking: having smoking experience or behaviors.

‡: Information was missing for N = 2503 patients (5.2%).

§: Information was missing for N = 4749 patients (9.9%), using the median for imputation.

||: Information was missing for N = 743 patients (1.5%), using the median for imputation.

#: Information was missing for N = 2682 patients (5.6%).

*: Information was missing for N = 28 patients (0.1%), using the median for imputation.

††: Information was missing for N = 28 patients (0.1%), using the median for imputation.

Table III. In-hospital outcomes in young (< 35 years) and old (≥35 years) ischemic stroke patients treated with IV tPA

Outcome	Total (N=48141 [100%])	young adults (< 35 years) (N=456 [0.9%])	old adults (≥35 years) (N=47685[99.1%])(REF)	Model	OR (95% CI)	P value
sICH	414 (0.9)	4 (0.9)	410 (0.9)	1	1.02 (0.38-2.74)	0.9678
				2	1.45 (0.54-3.94)	0.4612
				3	1.52 (0.56-4.13)	0.4136
In-hospital mortality	579 (1.2)	1 (0.2)	578 (1.2)	1	0.18 (0.03-1.28)	0.0861
				2	0.28 (0.04-2.01)	0.2066
				3	0.27 (0.04-1.97)	0.1953
Independent ambulation at discharge	26175 (54.4)	279 (61.2)	25896 (54.3)	1	1.33 (1.10-1.60)	0.0034
				2	1.09 (0.90-1.32)	0.384
				3	1.15 (0.92-1.42)	0.2173

Abbreviations: CI, confidence interval; IV tPA, intravenous recombinant tissue plasminogen activator ; OR, odds ratio.

Model 1: Logistic regression model without adjustment.

Model 2: Adjusted for gender, insurance, BMI, previous stroke/TIA, previous CAD/prior MI, diabetes, hypertension, have smoking experience or behavior, atrial fibrillation/flutter, glyated hemoglobin, diastolic blood pressure, systolic blood pressure, hypoglycemic drugs, antihypertensive drugs, antiplatelet drugs, and lipid-lowering drugs.

Model 3: Adjusted for in-hospital NIHSS score, gender, insurance, BMI, previous stroke/TIA, previous CAD/prior MI, diabetes, hypertension, have smoking experience or behavior, atrial fibrillation/flutter, glyated hemoglobin, diastolic blood pressure, blood pressure, hypoglycemic drugs, antihypertensive drugs, antiplatelet drugs, and lipid-lowering drugs. Patients (N= 2503) with missing values on NIHSS score were not included in this analysis.

Table IV. In-hospital outcomes in young(< 45 years) and old (≥45 years) ischemic stroke patients treated with IV tPA

Outcome	Total (N=48141 [100%])	young adults (< 45 years) (N=2244 [4.7%])	old adults (≥45 years) (N=45897[95.3%])(REF)	Model	OR (95% CI)	P value
sICH	414 (0.9)	8 (0.4)	406 (0.9)	1	0.40 (0.20-0.81)	0.0106
				2	0.54 (0.26-1.10)	0.0877
				3	0.44 (0.19-0.99)	0.048
In-hospital mortality	579 (1.2)	8 (0.4)	571 (1.2)	1	0.28 (0.14-0.57)	0.0004
				2	0.43 (0.21-0.87)	0.0197
				3	0.52 (0.26-1.07)	0.077
Independent ambulation at discharge	26175 (54.4)	1356 (60.4)	24819 (54.1)	1	1.30 (1.19-1.41)	<0.0001
				2	1.08 (0.98-1.18)	0.1082
				3	0.97 (0.88-1.08)	0.6096

Abbreviations: CI, confidence interval; IV tPA, intravenous recombinant tissue plasminogen activator ; OR, odds ratio.

Model 1: Logistic regression model without adjustment.

Model 2: Adjusted for gender, insurance, BMI, previous stroke/TIA, previous CAD/prior MI, diabetes, hypertension, have smoking experience or behavior, atrial fibrillation/flutter, glyated hemoglobin, diastolic blood pressure, systolic blood pressure, hypoglycemic drugs, antihypertensive drugs, antiplatelet drugs,and lipid-lowering drugs.

Model 3: Adjusted for in-hospital NIHSS score, gender, insurance, BMI, previous stroke/TIA, previous CAD/prior MI, diabetes, hypertension, have smoking experience or behavior, atrial fibrillation/flutter, glyated hemoglobin, diastolic blood pressure, blood pressure, hypoglycemic drugs, antihypertensive drugs, antiplatelet drugs, and lipid-lowering drugs. Patients (N= 2503) with missing values on NIHSS score were not included in this analysis.

STROBE Statement—checklist of items that should be included in reports of observational studies

Section/item	Item No	Recommendation	Page No.	Relevant text from manuscript
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	Page1,3,4	Title,Abstract/Para1-2
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	Page3-4	Abstract/Para2-4
Introduction				
Background/ rationale	2	Explain the scientific background and rationale for the investigation being reported	Page7	Introduction/Para1-2
Objectives	3	State specific objectives, including any prespecified hypotheses	Page7-8	Introduction/Para3
Methods				
Study design	4	Present key elements of study design early in the paper	Page8-9	Methods/Para1
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	Page9-10	Methods/Para2-4
Participants	6	(a) Cohort study —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up Case-control study —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls Cross-sectional study —Give the eligibility criteria, and the sources and methods of selection of participants	Page8-10	Methods/Para1-4
		(b) Cohort study —For matched studies, give matching criteria and number of exposed and unexposed Case-control study —For matched studies, give matching criteria and the number of controls per case		
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	Page9-10	Methods/Para3-4
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	Page8-11	Methods/Para1-6
Bias	9	Describe any efforts to address potential sources of bias	Page10-12	Methods/Para5-7
Study size	10	Explain how the study size was arrived at	Page8-9	Methods/Para1-2
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	Page10-11	Methods/Para5

Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	Page10-12	Methods/Para5-8
		(b) Describe any methods used to examine subgroups and interactions	Page10-11	Methods/Para5
		(c) Explain how missing data were addressed	Page11-12	Methods/Para7
		(d) Cohort study —If applicable, explain how loss to follow-up was addressed Case-control study —If applicable, explain how matching of cases and controls was addressed Cross-sectional study —If applicable, describe analytical methods taking account of sampling strategy	Page11-12	Methods/Para7
		(e) Describe any sensitivity analyses	Page11-12	Methods/Para7
Results				
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	Page12	Results/Para1
		(b) Give reasons for non-participation at each stage		Figure1
		(c) Consider use of a flow diagram		Figure1
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	Page12-15	Results/Para1-2
		(b) Indicate number of participants with missing data for each variable of interest	Page15	Results/table1
		(c) Cohort study —Summarise follow-up time (eg, average and total amount)		
Outcome data	15*	Cohort study —Report numbers of outcome events or summary measures over time	Page15-18	Results/Para3-6
		Case-control study —Report numbers in each exposure category, or summary measures of exposure		
		Cross-sectional study —Report numbers of outcome events or summary measures		
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	Page15-18	Results/Para3-6
		(b) Report category boundaries when continuous variables were categorized	Page15-17	Results/Para3-6
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period		
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	Page15-18	Results/Para3-6
Discussion				
Key results	18	Summarise key results with reference to study objectives	Page19-21	Discussion/Para1-5
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	Page21-22	Discussion/Para6

Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	Page19-22	Discussion/Para2-6
Generalisability	21	Discuss the generalisability (external validity) of the study results	Page21-22	Discussion/Para6
Other information				
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	Page23	Funding

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.